0001438133-23-000031 | 10-K | XBRL Viewer

Stockholders' Equity

12 Months Ended

Dec. 31, 2022

Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of the Company's common stock were reserved for future issuance at December 31, 2022 (in thousands):


Shares reserved for issuance upon conversion of Convertible Senior Notes			2,554
Shares underlying outstanding warrants			194
Shares underlying outstanding stock options			4,442
Shares underlying unvested restricted stock units			1,834
Shares authorized for issuance pursuant to awards granted under the ESPP			953
Shares authorized for future equity award grants			119
Total			10,096

Common Stock Warrants

Warrants outstanding to purchase shares of the Company's common stock as of December 31, 2022 were as follows:

Issue Date

Exercise Price Per Share

Warrants Outstanding

Expiration Date of Warrants Outstanding

March 2017

$23.50

193,788

March 2027

Each warrant allows the holder to purchase one share of the Company's common stock at the exercise price per share of the warrant. The Company issued 5,678 shares and 155,517 shares of its common stock, respectively, upon the exercise of warrants during the years ended December 31, 2022, and 2021, respectively.

Stock Plans

The Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) was originally approved by the Company’s board of directors in October 2013. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock and restricted stock units to individuals who are then employees, officers, directors or consultants of the Company.

Common Stock Options

The maximum term of stock options granted under the 2006 Plan and 2013 Plan is ten years. Common stock options have an exercise price equal to the closing price of the Company's common stock on the applicable award date. Stock options granted before the second quarter of 2022 generally vest over a four-year period as to 25% of the underlying shares on the first anniversary of the grant date, with the balance of the options vesting monthly over the following three years. Stock options granted during the second quarter of 2022 and thereafter vest over a three-year period as to 33% of the underlying shares on the first anniversary of the grant date, with the balance of the options vesting monthly over the following two years.

The following table summarizes stock option activities for the 2006 Plan and 2013 Plan:


	Total Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2019	7,174,927	$	38.40	8.45	$	181,408
Granted	1,130,040	$	83.55
Exercised	(2,339,467)	$	24.69		$	161,688
Canceled/forfeited/expired	(161,995)	$	27.00		$	4,516
Outstanding at December 31, 2020	5,803,505	$	52.08	7.90	$	268,649
Granted	355,008	$	86.68
Exercised	(1,128,791)	$	37.05		$	86,149
Canceled/forfeited/expired	(214,876)	$	76.29		$	6,963
Outstanding at December 31, 2021	4,814,846	$	57.08	7.07	$	452,081
Granted	83,008	$	65.28
Exercised	(280,275)	$	32.58		$	13,473
Canceled/forfeited/expired	(175,266)	$	77.93		$	2,143
Outstanding at December 31, 2022	4,442,313	$	57.95	6.12	$	30,236
Vested and expected to vest at December 31, 2022	4,423,803	$	57.87	6.12	$	30,236
Exercisable at December 31, 2022	3,701,918	$	54.08	5.82	$	30,234

Restricted Stock Units

Restricted stock units (RSUs) have a grant value equal to the closing price of the Company’s common stock on the award date. RSUs granted before March 2022 generally vest over a four-year period based only on service as to 25% of the underlying shares on the first anniversary of the award, with the balance of the RSUs vesting quarterly over the following three years. RSUs granted in March 2022 and thereafter generally vest over a three-year period based on continued service to the Company as to 33% of the underlying shares on the first anniversary of the award, with the balance of the RSUs vesting quarterly over the following two years. In addition, the Company granted 53,662 and 25,674 performance-based RSUs during the years ended December 31, 2022 and 2021, respectively. The performance-based RSUs have a grant value equal to the closing price of the Company’s common stock on the award date, and vest upon the Company’s actual performance relative to predefined performance metrics and subject to the awardee’s continuing service through the December 31, 2024 measurement date.

The following table summarizes RSU activities, which includes performance-based RSUs, for the 2013 Plan:


	Total RSUs	Weighted-Average Grant Date Fair Value		Aggregate Intrinsic Value (in thousands)
Unvested awards outstanding at December 31, 2019	—	$	—	$	—
Granted	134,694	$	82.82
Vested	(1,892)	$	82.34
Unvested awards outstanding at December 31, 2020	132,802	$	82.82	$	12,706
Granted	564,034	$	96.37
Vested	(53,957)	$	82.74
Canceled/forfeited	(32,148)	$	87.21
Unvested awards outstanding at December 31, 2021	610,731	$	95.08	$	91,927
Granted	1,542,859	$	67.09
Vested	(202,215)	$	91.99
Canceled/forfeited	(117,543)	$	84.20
Unvested awards outstanding at December 31, 2022	1,833,832	$	72.57	$	82,431
Awards expected to vest at December 31, 2022	1,797,999	$	72.62	$	80,820

The aggregate fair value of RSUs that vested during the years ended December 31, 2022, 2021 and 2020 was $12.7 million, $5.1 million, and $0.2 million, respectively, which represents the market value of the Company’s common stock on the date the RSUs vested. The number of RSUs vested includes shares of common stock the Company withheld on behalf of employees to satisfy the minimum statutory tax withholding requirements. RSUs that are expected to vest are net of estimated future forfeitures.

Employee Stock Purchase Plan

In October 2013, the Company adopted the ESPP, which enables eligible employees to purchase shares of the Company’s common stock using their after-tax payroll deductions, subject to certain conditions. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Eligible employees may contribute, through payroll deductions, up to 15% of their earnings for the purchase of common stock under the ESPP. The purchase price of common stock under the ESPP is the lesser of: (a) 85% of the fair market value of a share of the Company’s common stock on the first date of an offering or (b) 85% of the fair market value of a share of the Company’s common stock on the date of purchase. Generally, the ESPP consists of a two-year offering period with four six-month purchase periods.

During the years ended December 31, 2022 and 2021, 262,936 shares and 172,694 shares of our common stock, respectively, were purchased under the ESPP for proceeds of $12.7 million and $11.1 million, respectively.

Stock-Based Compensation

The following table summarizes the allocation of stock-based compensation expense included in the consolidated statements of operations for all stock-based compensation arrangements (in thousands):


	Year Ended December 31,
		2022		2021		2020
Cost of sales		$	7,685	$	6,434	$	8,210
Selling, general and administrative		57,196		43,567		41,563
Research and development		20,037		10,751		8,658
Total stock-based compensation expense		$	84,918	$	60,752	$	58,431

The total stock-based compensation expense capitalized as part of the cost of the Company’s inventories was $1.1 million at December 31, 2022, and $1.0 million at December 31, 2021.

At December 31, 2022, the total unamortized stock-based compensation expense of approximately $143.9 million will be recognized over the remaining weighted average vesting term of approximately 2.3 years.

The Company estimates the fair value of stock options using the Black-Scholes option-pricing model on the grant date. The assumptions used in the Black-Scholes option-pricing model were as follows:


		Stock Options
	Year Ended December 31,
		2022			2021			2020
Weighted average grant date fair value (per share)		$	42.16		$	56.89		$	54.20
Risk-free interest rate		2.7		%	1.0		%	0.6		%
Dividend yield		0.0		%	0.0		%	0.0		%
Expected volatility		72.0		%	75.1		%	74.6		%
Expected term (in years)		5.8			6.1			6.1

The Company records stock-based compensation expense associated with the ESPP using the Black-Scholes option-pricing model. Valuations are performed on the grant date at the beginning of the purchase period, which generally occurs in May and November of each year. The assumptions used in the Black-Scholes option-pricing model for the ESPP were as follows:


					ESPP
	Year Ended December 31,
		2022			2021			2020
Weighted average grant date fair value (per share)		$	21.89		$	38.19		$	36.83
Risk-free interest rate		3.4		%	0.2		%	0.2		%
Dividend yield		0.0		%	0.0		%	0.0		%
Expected volatility		56.9		%	44.2		%	60.3		%
Expected term (in years)		1.3			1.3			1.3

Risk-free Interest Rate. The risk-free interest rate assumption was based on the United States Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Expected Dividend Yield. The dividend yield is zero because the Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future.

Expected Volatility. The expected volatility was estimated based on a weighted-average of the Company’s actual historical volatility of its common stock measured over the expected term.

Expected Term. The Company utilized the simplified method for estimating the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the vesting term and the contractual term of the option. The Company estimates the expected term of the ESPP using expected life for each tranche during the two-year offering period.

The Company also estimates forfeitures at the time of grant, and revises those estimates in subsequent periods if actual forfeitures differ from its estimates. Historical data was used to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of Customers Accounted for 10% or More

The following table summarizes the percentages of total sales and accounts receivable, net for customers who accounted for 10% or more of the respective amounts for the periods presented:


	Total Sales						Accounts Receivable, net
	Year Ended December 31,						December 31,
	2022		2021		2020		2022		2021
Distributor B	11.6	%	11.9	%	15.9	%	12.8	%	11.2	%
Distributor C	*		*		12.9	%	*		*
Distributor D	*		*		*		10.4	%	*

* Amount related to the respective customer represented less than 10% for the period presented.

Schedule of Reconciliation of Change in Estimated Warranty Liabilities

The following table provides a reconciliation of the changes in product warranty liabilities for the years ended months ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of the period		$	30,401	$	22,075	$	16,724
Provision for warranties issued during the period		32,699		27,604		21,135
Settlements made during the period		(25,447)		(18,768)		(13,736)
Decreases in warranty estimates		(1,116)		(510)		(2,048)
Balance at end of the period		$	36,537	$	30,401	$	22,075

As of December 31, 2022 and December 31, 2021, total product warranty reserves were included in the following consolidated balance sheet accounts (in thousands):


	December 31, 2022		December 31, 2021

Other current liabilities	$	17,280	$	13,076
Other long-term liabilities	19,257		17,325
Total warranty reserve	$	36,537	$	30,401

Schedule of Earnings (Loss) Per Share, Basic and Diluted

For the years ended December 31, 2022, 2021 and 2020, the numerator and denominator of the diluted net income (loss) per share computation were calculated as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Net income (loss) - basic and diluted	$	(94,594)	$	15,566	$	(34,382)



Weighted average shares outstanding - basic	64,146		63,000		60,990
Dilutive common share equivalents:
Options to purchase common stock	—		1,129		—
Unvested restricted stock units	—		62		—
Warrants to purchase common stock	—		157		—
Awards to be granted under the ESPP	—		1		—

Weighted average shares outstanding - diluted	64,146		64,349		60,990

Schedule of Anti-Dilutive Securities

Potentially dilutive securities outstanding and not included in the calculation of diluted net income (loss) per share (because inclusion would be anti-dilutive) are as follows (in thousands, in common stock equivalent shares):


	Year Ended December 31,
		2022	2021	2020
Options to purchase common stock		1,138	3,124	5,021
Unvested restricted stock units		1,118	—	78
Warrants to purchase common stock		194	1	379
Awards granted under the ESPP		8	—	3
Convertible senior notes (if-converted)		2,554	2,554	1,605
		5,012	5,679	7,086

Debt

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Debt

Convertible Senior Notes

In May 2020, the Company entered into a purchase agreement with certain counterparties for the sale of an aggregate of $287.5 million principal amount of 1.50% Convertible Senior Notes due 2025 (Notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The proceeds from the issuance of the Notes were $244.6 million, net of debt issuance costs and cash used to pay the cost of the capped call transactions (Capped Call Transactions) discussed below.

The Notes are the Company’s senior unsecured obligations. Interest is payable in cash semi-annually in arrears beginning on November 1, 2020 at a rate of 1.50% per year. The Notes mature on May 1, 2025 unless repurchased, redeemed, or converted in accordance with their terms prior to the maturity date.

The Notes are convertible into cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, at an initial conversion rate of 8.8836 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of $112.57 (Conversion Price) per share of the Company’s common stock. The conversion rate is subject to customary adjustments for certain events as described in the Indenture governing the Notes. The Company expects to settle conversions through a combination settlement, which involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion.

The Company may not redeem the Notes before May 6, 2023. The Company has the option to redeem for cash all or any portion of the Notes on or after May 6, 2023 if the last reported sale price of the Company’s common stock has been at least 130% of the Conversion Price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest. No sinking fund is provided for the Notes.

Holders of the Notes may convert all or a portion of their Notes at their option before November 1, 2024, in multiples of $1,000 principal amounts, only under the following circumstances:

•if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price of the Notes on each such trading day;

•during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate of the Notes on such trading day;

•if the Company calls any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

•on the occurrence of specified corporate events.

On or after November 1, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Notes at any time, regardless of the foregoing circumstances.

Holders of the Notes who convert in connection with a make-whole fundamental change or in connection with a redemption are entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change, holders of the Notes may require us to repurchase all or a portion of the Notes at a price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest.

In accounting for the issuance of the Notes in 2020, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was recorded as a debt discount, which was being amortized to interest expense. On January 1, 2021, the Company early adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which is intended to simplify the accounting for convertible instruments. The Company adopted the new standard using the modified retrospective method, and accordingly, recorded a net reduction to accumulated deficit of $9.0 million, a decrease to additional paid-in capital of $85.8 million, and an increase to convertible senior notes, net - long-term of $76.8 million to reflect the impact of the accounting change. As of January 1, 2021, the Notes are accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.

The net carrying amount of the Notes on the consolidated balance sheets consisted of the following (in thousands):


	December 31, 2022		December 31, 2021
Principal amount	$	287,500	$	287,500
Unamortized debt issuance costs	(4,268)		(6,033)
Net carrying amount	$	283,232	$	281,467

The Notes will have a dilutive effect to the extent the average market price per share of common stock for a given reporting period exceeds the conversion price of $112.57. As of December 31, 2022, the if-converted value of the Notes did not exceed the principal amount. As of December 31, 2021, the if-converted value of the Notes exceeded the principal amount by $96.9 million.

As of December 31, 2022, the unamortized debt issuance costs of $4.3 million associated with the Notes will be amortized to interest expense, at an effective interest rate of 2.2% over the remaining period of approximately 2.3 years.

The following table details interest expense related to the Notes recognized for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Contractual interest expense		$	4,313	$	4,313	$	2,707
Amortization of debt issuance costs		1,896		1,727		652
Amortization of debt discount (1)		N/A		N/A		9,446
Total interest expense		$	6,209	$	6,040	$	12,805

(1) The debt discount was reversed upon the adoption of ASU No. 2020-06.

Capped Call Transactions

In connection with the issuance of the Notes, the Company entered into Capped Call Transactions in May 2020 with certain counterparties at a net cost of $34.1 million. The Capped Call Transactions are intended to reduce potential dilution to holders of the Company’s common stock beyond the conversion price of $112.57, up to a conversion price of $173.18 on any conversion of the Notes, or to offset any cash payments the Company is required to make in excess of the principal amount of such converted Notes, as the case may be, with such reduction or offset subject to a cap. The cap price of the Capped Call Transactions is initially $173.18 per share of the Company’s common stock, representing a premium of 100% above the last reported sale price of $86.59 per share of the Company’s common stock on May 12, 2020, and is subject to certain adjustments under the terms of the Capped Call Transactions. Conditions that cause adjustments to the initial strike price of the Capped Call Transactions mirror conditions that result in corresponding adjustments for the Notes.

For accounting purposes, the Capped Call Transactions are separate transactions, and not part of the terms of the Notes, while they are integrated for federal tax purposes. As these transactions met certain criteria under the applicable accounting guidance, the Capped Call Transactions were recorded in stockholders' equity and were not accounted for as derivatives. The cost of the Capped Call Transactions was recorded as a reduction of the Company’s additional paid-in capital in the Company’s consolidated balance sheet and will not be remeasured.

Line of Credit

On May 18, 2022, the Company entered into a three-year Revolving Line of Credit Agreement that provides the Company with a maximum principal borrowing amount of $100.0 million (the Line of Credit), reduced by any letters of credit issued and outstanding under a $15.0 million letter of credit sub-limit. The Line of Credit allows the Company to request advances thereunder, and to use the proceeds of such advances for general corporate purposes, including working capital and capital expenditures. The Line of Credit matures on the earlier of (i) May 18, 2025 or (ii) the Springing Maturity Date, unless renewed at maturity upon approval by the Company’s board of directors and the lender. The Springing Maturity Date is any date during the 91 days prior to the May 1, 2025 maturity date of the Company’s Convertible Senior Notes, that the Company does not satisfy a predefined liquidity threshold. During the term of the Line of Credit, the Company is required to maintain compliance with two financial maintenance covenants: a minimum consolidated interest coverage ratio and a maximum consolidated net leverage ratio. The Company was in compliance with these financial maintenance covenants as of December 31, 2022. The Line of Credit is secured by a first priority security interest in substantially all of the assets of the Company and its subsidiaries.

Advances drawn under the Line of Credit bear interest at an annual rate of (1) the SOFR Rate (as defined in the Line of Credit); plus (2) an applicable credit spread adjustment ranging from 0.10% to 0.25%; plus (3) an applicable margin ranging from 1.25% to 2.00%, and each advance will be payable on the Maturity Date with the interest on outstanding advances payable quarterly. The Credit Agreement also includes a commitment fee ranging from 0.20% to 0.35% per annum on the average daily unused amount of the Line of Credit, payable quarterly. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time before the maturity date, without premium or penalty.

As of December 31, 2022, the Company’s outstanding borrowings and available balance under the Line of Credit were as follows (in millions):


Maximum principal borrowing amount	$	100.0
Less:
Outstanding borrowings	—
Outstanding letters of credit	4.9
Total available balance	$	95.1

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Short-Term Investments

12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Short-Term Investments

The Company invests in marketable securities primarily consisting of debt instruments of the U.S. Government, U.S. Government-sponsored enterprises, and financial institutions and corporations with strong credit ratings. The following represents a summary of the estimated fair value of short-term investments at December 31, 2022 and December 31, 2021 (in thousands):


At December 31, 2022	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	213,105	$	3	$	(1,947)	$	211,161
Commercial paper	112,812		6		(208)		112,610
U.S. Government-sponsored enterprises	100,602		21		(615)		100,008
Corporate debt securities	18,218		—		(104)		18,114
Supranational bonds	2,504		—		(13)		2,491
Total	$	447,241	$	30	$	(2,887)	$	444,384


At December 31, 2021	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	222,206	$	—	$	(482)	$	221,724
Commercial paper	218,391		14		(24)		218,381
U.S. Government-sponsored enterprises	50,773		1		(88)		50,686
Corporate debt securities	58,881		—		(45)		58,836
Supranational bonds	3,003		—		—		3,003
Total	$	553,254	$	15	$	(639)	$	552,630

The contractual maturities of available-for-sale debt securities as of December 31, 2022, were as follows (in thousands):


	Years to Maturity
At December 31, 2022	Within One Year		One to Two Years		Estimated Fair Value
U.S. Treasury securities	$	202,855	$	8,306	$	211,161
Commercial paper	112,610		—		112,610
U.S. Government-sponsored enterprises	73,292		26,716		100,008
Corporate debt securities	13,190		4,924		18,114
Supranational bonds	2,491		—		2,491
Total	$	404,438	$	39,946	$	444,384

The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company’s ability and intent to use any of those marketable securities to satisfy the Company’s liquidity requirements.

The Company reviews the portfolio of available-for-sale debt securities quarterly to determine if any investment is impaired due to changes in credit risk or other potential valuation concerns. Unrealized losses on available-for-sale debt securities at December 31, 2022 were primarily due to the recent increase in market interest rates. The Company does not intend to sell the available-for-sale debt securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell these debt securities before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, the Company did not record an allowance for credit losses related to its available-for-sale debt securities at December 31, 2022.

Stockholders' Equity - Restricted Stock Units (RSUs) (Detail) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested awards outstanding at beginning balance (in shares)	610,731	132,802	0
Granted (in shares)	1,542,859	564,034	134,694
Vested (in shares)	(202,215)	(53,957)	(1,892)
Canceled/forfeited/expired (in shares)	(117,543)	(32,148)
Unvested awards outstanding at ending balance (in shares)	1,833,832	610,731	132,802
Awards expected to vest (in shares)	1,797,999
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested awards outstanding at beginning balance (in dollars per share)	$ 95.08	$ 82.82	$ 0
Granted (in dollars per share)	67.09	96.37	82.82
Vested (in dollars per share)	91.99	82.74	82.34
Canceled/forfeited/expired (in dollars per share)	84.20	87.21
Unvested awards outstanding at ending balance (in dollars per share)	72.57	$ 95.08	$ 82.82
Awards expected to vest (in dollars per share)	$ 72.62
Aggregate intrinsic value outstanding balance	$ 82,431	$ 91,927	$ 12,706	$ 0
Awards expected to vest, aggregate intrinsic value	$ 80,820

Fair Value Measurements

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

Authoritative guidance on fair value measurements defines fair value, and provides a consistent framework for measuring fair value and for disclosures of each major asset and liability category measured at fair value on either a recurring or a nonrecurring basis. Fair value is intended to reflect an assumed exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:


Level 1:						Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2:						Inputs, other than quoted prices in active markets, that are observable either directly or indirectly for substantially the full term of the asset or liability.

Level 3:						Unobservable inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which require the reporting entity to develop its own valuation techniques that require input assumptions.

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation techniques used by the Company to determine such fair value (in thousands):


	Fair Value Measurements at December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents(1)	$	150,742	$	150,742	$	—	$	—
U.S. Treasury securities	211,161		211,161		—		—
Commercial paper	112,610		—		112,610		—
U.S. Government-sponsored enterprises	100,008		—		100,008		—
Corporate debt securities	18,114		—		18,114		—
Supranational bonds	2,491		—		2,491		—
Total assets	$	595,126	$	361,903	$	233,223	$	—


	Fair Value Measurements at December 31, 2021
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents(1)	$	48,286	$	48,286	$	—	$	—
U.S. Treasury securities	221,724		221,724		—		—
Commercial paper	218,381		—		218,381		—
U.S. Government-sponsored enterprises	50,686		—		50,686		—
Corporate debt securities	58,836		—		58,836		—
Supranational bonds	3,003		—		3,003		—
Total assets	$	600,916	$	270,010	$	330,906	$	—
Liabilities
Common stock warrants(2)	$	147	$	—	$	—	$	147
Total liabilities	$	147	$	—	$	—	$	147

(1)Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.

(2)Included in other current liabilities on the Company’s consolidated balance sheet.

The Company’s Level 2 financial instruments are valued using market prices on less active markets with observable valuation inputs such as interest rates and yield curves. The Company obtains the fair value of Level 2 financial instruments from quoted market prices, calculated prices or quotes from third-party pricing services. The Company validates these prices through independent valuation testing and review of portfolio valuations provided by the Company’s investment managers.

The Company's Level 3 liabilities at December 31, 2021 included outstanding Series A warrants to purchase 1,000 shares of the Company’s common stock, issued by the Company in connection with the public offering of common stock in October 2017 and which expired in October 2022. The fair value of the outstanding Series A common stock warrants was remeasured at each financial reporting date using a Black-Scholes pricing model with any changes in fair value being recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive income (loss). The assumptions used to estimate the fair values of the outstanding Series A warrants at December 31, 2021 were as follows:



	December 31, 2021
Risk-free interest rate	0.3	%
Dividend yield	0.0%
Expected volatility	39.1	%
Expected term (in years)	0.8

The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the years ended December 31, 2022, 2021 and 2020 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of period		$	147	$	14,261	$	23,509
(Gain) loss recognized from the change in fair value of common stock warrants		(147)		1,386		17,087
Common stock warrants exercised during the period		—		(15,500)		(26,335)
Balance at end of period		$	—	$	147	$	14,261

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt - Components of Convertible Note (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 31, 2020
Debt Instrument [Line Items]
Unamortized debt issuance costs			$ (8,809,000)
Convertible senior notes \| Convertible senior notes
Debt Instrument [Line Items]
Principal amount	$ 287,500,000	$ 287,500,000		$ 287,500,000
Unamortized debt issuance costs	(4,268,000)	(6,033,000)
Net carrying amount	$ 283,232,000	$ 281,467,000

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Short-Term Investments (Tables)

12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Schedule of Estimated Fair Value of Short-Term Investments

The following represents a summary of the estimated fair value of short-term investments at December 31, 2022 and December 31, 2021 (in thousands):


At December 31, 2022	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	213,105	$	3	$	(1,947)	$	211,161
Commercial paper	112,812		6		(208)		112,610
U.S. Government-sponsored enterprises	100,602		21		(615)		100,008
Corporate debt securities	18,218		—		(104)		18,114
Supranational bonds	2,504		—		(13)		2,491
Total	$	447,241	$	30	$	(2,887)	$	444,384


At December 31, 2021	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
Available-for-sale securities:
U.S. Treasury securities	$	222,206	$	—	$	(482)	$	221,724
Commercial paper	218,391		14		(24)		218,381
U.S. Government-sponsored enterprises	50,773		1		(88)		50,686
Corporate debt securities	58,881		—		(45)		58,836
Supranational bonds	3,003		—		—		3,003
Total	$	553,254	$	15	$	(639)	$	552,630

Schedule of Contractual Maturities of Available -For-Sale Debt Securities

The contractual maturities of available-for-sale debt securities as of December 31, 2022, were as follows (in thousands):


	Years to Maturity
At December 31, 2022	Within One Year		One to Two Years		Estimated Fair Value
U.S. Treasury securities	$	202,855	$	8,306	$	211,161
Commercial paper	112,610		—		112,610
U.S. Government-sponsored enterprises	73,292		26,716		100,008
Corporate debt securities	13,190		4,924		18,114
Supranational bonds	2,491		—		2,491
Total	$	404,438	$	39,946	$	444,384

Composition of Certain Financial Statement Items - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense related to property and equipment	$ 12.3	$ 11.7	$ 9.2
Amortization expense related to intangible assets	2.0	$ 2.2	$ 1.2
Estimated annual amortization for 2023	1.9
Estimated annual amortization for 2024	1.9
Estimated annual amortization for 2025	$ 0.9

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal and Regulatory Matters In May 2020, we were named as a defendant in three California state court class action lawsuits arising from a phishing incident that occurred in January 2020. Collectively, these lawsuits sought statutory, compensatory, actual, and punitive damages; equitable relief, including restitution; pre- and post-judgment interest; injunctive relief; and attorney fees, costs, and expenses from us. On July 24, 2020, these three lawsuits were consolidated into a single case in the Superior Court of the State of California in the County of San Bernardino entitled Joseph Deluna et al. v. Tandem Diabetes Care, Inc. The consolidated case alleged violations of the Confidentiality of Medical Information Act (CMIA), CCPA, California’s Unfair Competition Law (UCL), and breach of contract. We filed a demurrer on all claims, which was heard by the Court on October 20, 2020, and our demurrer to the CCPA claim was sustained. The plaintiffs filed a motion for class certification on January 7, 2022 and we filed a motion for summary adjudication on the CMIA claim on April 7, 2022. On February 8, 2023, the Court granted plaintiffs’ request to dismiss their remaining two claims with prejudice, and dismissed the motion for class certification, terminating the case in the Superior Court. The plaintiffs have to decide whether to appeal the Court’s decision granting our motion for summary adjudication. Although we intend to vigorously defend against these claims, there is no guarantee that we will prevail. Accordingly, we are unable to determine the ultimate outcome of these lawsuits or determine the amount or range of potential losses associated with the lawsuits. From time to time, we are involved in various other legal proceedings, regulatory matters, and other disputes or claims arising from or related to claims incident to the normal course of our business activities, including actions with respect to intellectual property, data privacy, employment, regulatory, product liability and contractual matters. Although the results of such legal proceedings and claims cannot be predicted with certainty, we believe we are not currently a party to any legal proceeding(s) which, if determined adversely to us, would, individually or taken together, have a material adverse effect on our business, operating results, financial condition or cash flows. However, regardless of the merit of the claims raised or the outcome, legal proceedings may have an adverse impact on us as a result of defense and settlement costs, diversion of management time and resources, and other factors. Letters of Credit In connection with one of the Company’s operating leases (see Note 6, “Leases”), the Company has a $4.9 million unsecured irrevocable standby letter of credit arrangement with a bank (see Note 7, “Debt”), under which the landlord of the building is the beneficiary. The Company is required to maintain the standby letter of credit throughout the term of the lease, which expires in April 2035. Purchase Obligations The Company has agreements with suppliers and other parties to purchase inventory, other goods and services and long-lived assets. Product inventory obligations consist primarily of purchase order commitments for raw materials used in the production of insulin pumps and cartridges, and finished goods infusion sets. Cancellation of outstanding purchase orders is generally allowed under the standard terms of our purchase order agreements, but may require payment of costs incurred through the date of cancellation. At December 31, 2022, obligations under our purchase agreements totaled approximately $351.4 million, of which approximately $320.3 million is scheduled to be received and become payable within one-year.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Common Stock

Additional Paid-in Capital

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Cumulative Effect, Period of Adoption, Adjustment

^[1]

Beginning balance (in shares) at Dec. 31, 2019

59,396,000

Beginning balance at Dec. 31, 2019

$ 194,979

$ 59

$ 819,626

$ 122

$ (624,828)

Increase (Decrease) in Stockholders' Equity

Exercise of stock options (in shares)

2,339,467

2,341,000

Exercise of stock options

$ 57,750

$ 2

57,748

Issuance of common stock under Employee Stock Purchase Plan (in shares)

303,000

Issuance of common stock under Employee Stock Purchase Plan

9,116

$ 1

9,115

Exercise of common stock warrants (in shares)

295,000

Exercise of common stock warrants

2,950

Fair value of common stock warrants at time of exercise

26,335

Equity component of convertible senior notes issuance, net of issuance costs

85,803

Payment for capped call transactions related to convertible senior notes

(34,069)

Stock-based compensation expense

57,725

Unrealized loss on short-term investments

(20)

Foreign currency translation gains (losses)

118

Net income (loss)

(34,382)

Ending balance (in shares) at Dec. 31, 2020

62,335,000

Ending Balance at Dec. 31, 2020

$ 366,305

$ (76,754)

$ 62

1,025,233

$ (85,803)

220

(659,210)

$ 9,049

Increase (Decrease) in Stockholders' Equity

Accounting Standards Update [Extensible List]

Accounting Standards Update 2020-06

Exercise of stock options (in shares)

1,128,791

1,129,000

Exercise of stock options

$ 41,823

$ 2

41,821

Vesting of restricted stock units, net of shares withheld for taxes (in shares)

38,000

Vesting of restricted stock units, net of shares withheld for taxes

(1,551)

Issuance of common stock under Employee Stock Purchase Plan (in shares)

173,000

Issuance of common stock under Employee Stock Purchase Plan

11,069

Exercise of common stock warrants (in shares)

158,000

Exercise of common stock warrants

899

Fair value of common stock warrants at time of exercise

15,500

Stock-based compensation expense

61,091

Unrealized loss on short-term investments

(693)

Foreign currency translation gains (losses)

(143)

Net income (loss)

15,566

Ending balance (in shares) at Dec. 31, 2021

63,833,000

Ending Balance at Dec. 31, 2021

$ 433,112

$ 64

1,068,259

(616)

(634,595)

Increase (Decrease) in Stockholders' Equity

Exercise of stock options (in shares)

280,275

280,000

Exercise of stock options

$ 9,131

9,130

Vesting of restricted stock units, net of shares withheld for taxes (in shares)

131,000

Vesting of restricted stock units, net of shares withheld for taxes

(4,374)

Issuance of common stock under Employee Stock Purchase Plan (in shares)

263,000

Issuance of common stock under Employee Stock Purchase Plan

12,713

Exercise of common stock warrants (in shares)

6,000

Exercise of common stock warrants

Stock-based compensation expense

85,077

Unrealized loss on short-term investments

(2,233)

Foreign currency translation gains (losses)

1,032

Net income (loss)

(94,594)

Ending balance (in shares) at Dec. 31, 2022

64,513,000

Ending Balance at Dec. 31, 2022

$ 439,947

$ 65

$ 1,170,888

$ (1,817)

$ (729,189)

[1]	The Company adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, effective January 1, 2021 (see Note 7, “Debt”).

Acquisitions (Details) - USD ($) $ in Thousands		12 Months Ended
Acquisitions (Details) - USD ($) $ in Thousands	Jul. 21, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Acquired in-process research and development expenses		$ 31,039	$ 0	$ 0
Capillary Biomedical
Business Acquisition [Line Items]
Asset acquisition, purchase price	$ 24,700
Long term debt assumed	4,700
Acquired in-process research and development expenses	$ 31,000

Business Segment and Geographic Information - Geographical Markets (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total Sales	$ 220,502	$ 209,996	$ 801,217	$ 702,799	$ 498,830
United States
Disaggregation of Revenue [Line Items]
Total Sales			588,765	524,907	415,680
Outside the United States
Disaggregation of Revenue [Line Items]
Total Sales			$ 212,452	$ 177,892	$ 83,150

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event AMF Medical Acquisition On December 10, 2022, the Company, entered into a Share Purchase Agreement (the “Purchase Agreement”) with AMF Medical SA, a corporation organized and existing under the laws of Switzerland (“AMF Medical”), and its shareholders to acquire all of the registered shares of AMF Medical (the “Transaction”), the privately held Swiss developer of the Sigi Patch Pump. The Sigi Patch Pump, designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges, is under development and not commercially available. On January 19, 2023, the Company completed the acquisition of AMF Medical, pursuant to the terms of the Purchase Agreement. The total aggregate consideration for the Transaction includes a previous strategic investment of Swiss Francs (“CHF”) 8.0 million paid in the third quarter of 2022 (see Note 2, “Strategic Investments”), a cash payment of CHF 62.4 million paid at the closing of the Transaction, and additional contingent earnout payments. The additional earnout payments of up to CHF 129.6 million, in aggregate, become payable upon the achievement of certain milestones and are comprised of a payment of up to CHF 38.4 million upon the successful completion of key development milestones over the next two years, and a payment of up to CHF 91.2 million upon obtaining regulatory clearance of an automated controller enabled (ACE) pump by the United States Food and Drug Administration. The Company funded the initial closing payment using existing cash balances, and is in the process of determining the accounting treatment for the acquisition.

Composition of Certain Financial Statement Items - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total cost	$ 124,727	$ 99,555
Less: accumulated depreciation and amortization	(56,175)	(49,169)
Total property and equipment, net	68,552	50,386
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total cost	35,828	25,245
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total cost	13,772	9,943
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total cost	12,330	11,544
Manufacturing and scientific equipment
Property, Plant and Equipment [Line Items]
Total cost	$ 62,797	$ 52,823

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 1,742,000	$ 335,000	$ (1,900,000)
Income (loss) before taxes	(92,852,000)	15,901,000	(36,282,000)
Valuation allowance	162,726,000	146,423,000
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits	15,000,000
Accrual interest and penalties	$ 0	$ 0	$ 0
Minimum
Operating Loss Carryforwards [Line Items]
Income tax realization	50.00%
California
Operating Loss Carryforwards [Line Items]
NOL carryforwards subject to expiration	$ 169,500,000
Federal
Operating Loss Carryforwards [Line Items]
NOL carry forwards amount	193,100,000
NOL carryforwards not subject to expiration	95,600,000
NOL carryforwards subject to expiration	97,500,000
Federal \| Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, amount	18,100,000
State and Local
Operating Loss Carryforwards [Line Items]
NOL carry forwards amount	255,900,000
California \| Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, amount	$ 20,100,000

Business Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Schedule of Disaggregation of Revenue

The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped (in thousands):


	Year Ended December 31,
		2022		2021		2020
United States		$	588,765	$	524,907	$	415,680
Outside the United States		212,452		177,892		83,150
Total Sales		$	801,217	$	702,799	$	498,830

Summary of Significant Accounting Policies - Customers Accounted for 10% or More (Detail) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total Sales \| Distributor B
Concentration Risk [Line Items]
Customers accounted for 10% or more	11.60%	11.90%	15.90%
Total Sales \| Distributor C
Concentration Risk [Line Items]
Customers accounted for 10% or more			12.90%
Accounts Receivable, net \| Distributor B
Concentration Risk [Line Items]
Customers accounted for 10% or more	12.80%	11.20%
Accounts Receivable, net \| Distributor D
Concentration Risk [Line Items]
Customers accounted for 10% or more	10.40%

Summary of Significant Accounting Policies - Numerator and Denominator of the Basic and Diluted Net Income (Loss) Per Share Computations (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) - basic	$ (15,853)	$ 10,808	$ (94,594)	$ 15,566	$ (34,382)
Net income (loss) - diluted	$ (15,853)	$ 10,840	$ (94,594)	$ 15,566	$ (34,382)
Weighted average shares outstanding - basic (in shares)	64,384	63,650	64,146	63,000	60,990
Dilutive common shares equivalents - Warrants to purchase common stock (in shares)			0	157	0
Weighted average shares outstanding - diluted (in shares)	64,384	65,927	64,146	64,349	60,990
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			0	1,129	0
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			0	62	0
Awards to be granted under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common stock equivalents - Incremental common shares attributable to dilutive effect (in shares)			0	1	0

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

The income (loss) before provision for income taxes for the Company’s operations was as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
United States	$	(94,033)	$	15,211	$	(36,667)
Foreign	1,181		690		385
Income (loss) before provision for income taxes	$	(92,852)	$	15,901	$	(36,282)

The components of income tax expense (benefit) were as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Current:
Federal	$	216	$	—	$	—
State	1,228		174		75
Foreign	298		161		151
Total current tax expense	1,742		335		226
Deferred:
Federal	—		—		(1,760)
State	—		—		(366)
Foreign	—		—		—
Total deferred income tax benefit	—		—		(2,126)
Income tax expense (benefit)	$	1,742	$	335	$	(1,900)

The expense (benefit) for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Income tax expense (benefit) at federal statutory rate (1)	$	(19,499)	$	3,339	$	(7,619)
State income tax, net of federal benefit	(926)		(254)		(2,792)
Warrants revaluation	(31)		356		3,588
Research and development credits	(6,263)		(5,703)		(5,330)
Section 382 limitation	—		(97)		1,021
Stock-based compensation	2,282		(7,609)		(18,309)
Officers' compensation	2,931		4,024		2,612
Acquired IPR&D expenses	6,518		—		—
Other	962		124		479
Change in valuation allowance	15,768		6,155		24,450
Income tax expense (benefit)	$	1,742	$	335	$	(1,900)

(1)For the years ended December 31, 2022, 2021 and 2020, the federal statutory tax rate was 21%.

Significant components of the Company’s net deferred income tax assets at December 31, 2022 and 2021 are shown in the table below (in thousands). The Company assesses all available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative book loss incurred over the three-year period ended December 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as projections for future growth. On the basis of this analysis, a valuation allowance of $162.7 million and $146.4 million at December 31, 2022 and 2021, respectively, was recorded to offset the net deferred tax asset as realization of such asset is uncertain. However, the amount of the deferred tax asset considered realizable could be adjusted if estimates of future taxable income during the carryforward period are increased, or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as the Company’s projections for future growth.


	December 31,
	2022		2021
Deferred tax assets:
Net operating loss (NOL) carryforwards	$	54,598	$	78,961
Research and development tax credits carryforwards	22,400		16,761
Capitalized research and development expenses	29,760		5,135
Accrued compensation	34,378		28,970
Lease liabilities	32,738		8,012
Other	20,927		20,608
Total deferred tax assets	194,801		158,447
Deferred tax liabilities:
Operating lease right-of-use assets	(26,505)		(6,637)
Fixed assets	(4,467)		(3,847)
Other	(1,103)		(1,540)
Total deferred tax liabilities	(32,075)		(12,024)
Less valuation allowance	(162,726)		(146,423)
Net deferred tax assets	$	—	$	—

As of December 31, 2022, the Company had accumulated federal and state NOL carryforwards of approximately $193.1 million, and $255.9 million, respectively, Of the total federal net operating loss carryforwards, approximately $95.6 million were generated after January 1, 2018, and therefore do not expire. NOL generated after January 1, 2018, is subject to 80% limitation in accordance with the Tax Cuts and Jobs Act of 2017. The remaining federal net operating loss carryforwards of $97.5 million will begin to expire in 2033, and state tax loss carryforwards continue to expire in 2023, unless previously utilized. The remaining California NOL carryforwards of $169.5 million will begin expiring in 2031. The Company had no foreign tax loss carryforwards as of December 31, 2022.

The Company also has federal and California research credit carryforwards of approximately $18.1 million and $20.1 million, respectively, as of December 31, 2022. The federal research credit carryforwards will begin expiring in 2038, unless previously utilized. The California research credit will carry forward indefinitely.

Utilization of the Company's net operating loss and research credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations may result in the expiration of net operating loss carryforwards before utilization. The Company has completed analyses through December 31, 2021 to determine whether its net operating losses and credits are likely to be limited by Section 382. Based on the 2018 study completed in 2019, the Company determined that an ownership change, as defined under Section 382, occurred in 2018 and the resulting limitation significantly reduced the Company’s ability to utilize its net operating loss and credit carryovers before they expire. As a result, in 2019 the Company reduced its deferred tax assets for the net operating loss and research credit carryforwards that were projected to expire unused with a corresponding offset to the valuation allowance recorded against such assets. Additionally, future ownership changes under Section 382 may also limit the Company's ability to fully utilize any remaining tax benefits.

The evaluation of uncertainty in a tax position is a two-step process. The first step involves recognition. The Company determines whether it is more likely than not that a tax position will be sustained upon tax examination, including resolution of any related appeals or litigation, based on only the technical merits of the position. The technical merits of a tax position are derived from both statutory and judicial authority (legislation and statutes, legislative intent, regulations, rulings, and case law) and their applicability to the facts and circumstances of the tax position. If a tax position does not meet the more-likely-than-not recognition threshold, the benefit of that position is not recognized in the financial statements. The second step is measurement. A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate resolution with a taxing authority.

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2022, 2021 and 2020 (in thousands):


	Year Ended December 31,
	2022		2021		2020
Gross unrecognized tax benefits at the beginning of the year	$	13,589	$	10,107	$	6,580
Increases related to current year positions	3,403		3,482		2,234
Increases (decreases) related to prior year positions	(6)		—		1,293
Gross unrecognized tax benefits at the end of the year	$	16,986	$	13,589	$	10,107

As of December 31, 2022, the Company had $15.0 million of unrecognized tax benefits that, if recognized and realized would impact the effective tax rate, subject to the valuation allowance.

The Company’s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the Company’s consolidated balance sheets and has not recognized interest and penalties in the consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020. The Company does not expect any significant increases or decreases, other than the potential reduction as a result of the Section 382 limitation, to its unrecognized tax benefits within the next 12 months.

The Company is subject to taxation in the United States and various foreign and state jurisdictions. Prior to 2018, the losses were all attributable to the United States. The Company’s tax years from 2006 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized NOLs and research and development credits.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting PoliciesThere have been no material changes to the Company’s significant accounting policies during the year ended December 31, 2022, except for adding the accounting policies related to an asset acquisition and the recently launched Tandem Choice technology access program (Tandem Choice), which are included herein.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.

Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty to be cash equivalents.

Short-Term Investments

The Company’s short-term investments are classified as available-for-sale securities. Such securities are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. The Company’s short-term investments consist of Level 1 and Level 2 financial instruments in the fair value hierarchy. The net unrealized gains or losses on available-for-sale securities that are not related to credit factors are reported as a component of other comprehensive income (loss) within the statements of operations and accumulated other comprehensive income (loss) as a separate component of stockholders’ equity on the consolidated balance sheets. The Company determines realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations.

The Company reviews its available-for-sale debt securities for credit losses quarterly, considering a variety of factors, including the significance of the decline in value as compared to the amortized cost basis; underlying factors contributing to a decline in the prices of securities in a single asset class; the security’s relative performance versus its peers, sector or asset class; the market and economy in general; views of external investment managers; news or financial information that has been released specific to the investee; and the outlook for the overall industry in which the investee operates. Losses on available-for-sale debt securities as a result of credit factors are recognized by recording an impairment loss as a component of other income or expense within the consolidated statements of operations and a corresponding allowance for credit losses. The Company has not recognized any impairment losses related to its short-term investments during the years ended December 31, 2022, 2021 and 2020.

Accounts Receivable

The Company grants credit to various customers in the ordinary course of business and is paid directly by customers who use its products, distributors and third-party insurance payors. The Company maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, forecasts about the future, and various assumptions and estimates that are believed to be reasonable under the circumstances, including credit risks as a result of the coronavirus pandemic, recessionary concerns, changes in discretionary spending, increased interest rates, and other macroeconomic factors. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains deposit accounts in federally insured financial institutions in excess of federally insured limits. The Company also maintains investments in money market funds that are not federally insured. Additionally, the Company has established guidelines regarding investment instruments and their maturities, which are designed to maintain preservation of principal and liquidity.

The following table summarizes the percentages of total sales and accounts receivable, net for customers who accounted for 10% or more of the respective amounts for the periods presented:


	Total Sales						Accounts Receivable, net
	Year Ended December 31,						December 31,
	2022		2021		2020		2022		2021
Distributor B	11.6	%	11.9	%	15.9	%	12.8	%	11.2	%
Distributor C	*		*		12.9	%	*		*
Distributor D	*		*		*		10.4	%	*

* Amount related to the respective customer represented less than 10% for the period presented.

Fair Value of Financial Instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and employee-related liabilities are reasonable estimates of their fair values because of the short-term nature of these assets and liabilities. Short-term investments are carried at fair value. The carrying value and estimated fair value of certain of the Company’s common stock warrants was determined using the Black-Scholes pricing model as of December 31, 2021 (see Note 5, “Fair Value Measurements”).

The Company’s convertible senior notes are carried at amortized cost on the consolidated balance sheets (see Note 7, “Debt”). The Company measures the fair value of its convertible senior notes for disclosure purposes. The Company estimated the fair value of its convertible senior notes to be $260.5 million and $430.0 million at December 31, 2022 and December 31, 2021, respectively, based on Level 2 quoted market prices as of those dates

Valuation of Inventories

Inventories are valued at the lower of cost or net realizable value, determined by the first-in, first-out method. Inventory is recorded using standard cost, including material, labor and overhead costs. The Company periodically reviews inventories for potential impairment and adjusts inventory for potentially excess or obsolete goods to state inventories at their net realizable value. Factors influencing these adjustments include quantities on hand and firm purchase commitments, expectations of future use, judgments based on quality control testing data and assessments of the likelihood of scrapping or obsoleting certain inventories based on future demand for its products and market conditions.

Long-Lived Assets

Property and Equipment

Property and equipment, which primarily consist of office furniture and equipment, manufacturing equipment, scientific equipment, computer equipment, and leasehold improvements, are stated at cost, less accumulated depreciation. Property and equipment are depreciated over the estimated useful lives of the assets, generally three to seven years, using the straight-line method. Leasehold improvements and related equipment are amortized over the lesser of the estimated useful lives of the assets or the remaining lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised. Maintenance and repair costs are expensed as incurred.

Operating Lease Right-of-Use Assets and Liabilities

Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842 Leases, the Company combines lease and non-lease components. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the Company’s consolidated balance sheets. Landlord improvement allowances and other similar lease incentives are recorded as a reduction of the right-of-use leased assets, and are amortized on a straight-line basis as a reduction to operating lease costs.

Intangible Assets Subject to Amortization

Finite-lived intangible assets (see Note 4, “Composition of Certain Financial Statement Items”) are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recognized over their estimated useful lives on a straight-line basis.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, right-of-use lease assets, and acquired intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined using unobservable (Level 3) inputs, including discounted cash flow models, future estimated sublease income, and third-party independent appraisals, as considered necessary. There is uncertainty in the projected undiscounted future cash flows used in the Company’s impairment review analysis, which requires the use of estimates and assumptions. If actual performance does not achieve the projections, or if the assumptions used change in the future, the Company may be required to recognize additional impairment charges in future periods. Other than the impairment of operating lease right-of-use assets recognized in the fourth quarter of 2022 (see Note 6, “Leases”), there were no impairments of long-lived assets, including acquired intangible assets, during the years ended December 31, 2022 and 2021.

Strategic Investments

During the third quarter of 2022, the Company made an investment of Swiss Francs (“CHF”) 8.0 million, or $8.3 million, in AMF Medical SA (“AMF Medical”), a privately held company. The investment is included as a component of other long-term assets on the consolidated balance sheet at December 31, 2022. On January 19, 2023, the Company completed the acquisition of AMF Medical, pursuant to the terms of the Purchase Agreement entered into on December 13, 2022 (see Note 15, “Subsequent Event”).

During the second quarter of 2021, the Company made an $8.1 million equity investment in a private company, which represented less than 5% of the outstanding equity of that company as of the date of investment. The investment is carried at cost minus impairment, if any, adjusted for changes in observable prices and is included as a component of other long-term assets on the consolidated balance sheets. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions.

Revenue Recognition

Revenue is generated primarily from sales of insulin pumps, disposable insulin cartridges and infusion sets to individual customers with third-party insurance coverage and through a network of distributors that resell the products to insulin-dependent diabetes customers. The Company recognizes revenue when it transfers control of the promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, net of estimated returns.

Revenue Recognition for Arrangements with Multiple Performance Obligations

The Company considers the individual deliverables in its product offering as separate performance obligations. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company allocates the consideration to the individual performance obligations and recognizes the consideration based on when the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. Generally, insulin pumps, cartridges, infusion sets, and accessories are deemed performance obligations that are satisfied at a point in time when the customer obtains control of the promised good, which typically is upon shipment for our distributor arrangements and upon receipt for sales directly to individual customers. Complementary products, such as t:connect and the Tandem Device Updater, are considered distinct performance obligations that are satisfied over time, as access and support for these products is provided throughout the typical four-year warranty period of the insulin pumps. Accordingly, revenue related to the complementary products is deferred and recognized over a four-year period. Where there is no standalone value for the complementary product, the Company determines its value by applying the expected cost plus a margin approach and then allocates the residual to the insulin pumps.

Tandem Choice Program

In September 2022, the Company announced and launched a new technology access program, (Tandem Choice) that provides eligible, in-warranty t:slim X2 customers in the United States with the flexibility to obtain the newest hardware platform when it is commercially available. Participating customers have the right to purchase the alternative Tandem pump for a fee (the Choice Right). The Tandem Choice expires on December 31, 2024.

For purposes of evaluating the Tandem Choice, in accordance with ASC 606, the Company has determined that the ability for a customer to upgrade to a new technology, represents a material right because the pricing inherent in such option provides the customer with a discount that is incremental to the range of discounts that would otherwise be granted for the related goods and services to comparable customers. The standalone selling price for the Choice Right was estimated based on the adjusted market assessment approach and contemplates the likelihood that the respective option will be exercised. At December 31, 2022, $6.8 million was allocated to the material right and recorded in current deferred revenue on the consolidated balance sheet.

Sales Returns

The Company offers a 90-day right of return to customers in the U.S. and Canada from the date of shipment of its insulin pumps, provided a physician’s confirmation of the medical reason for the return is received. Estimated allowances for sales returns are based on historical returned quantities as compared to pump shipments in those same periods of return, adjusted for known or expected changes in the marketplace when appropriate. The amount recorded in deferred revenue on the Company’s consolidated balance sheets for allowances for sales returns was $0.5 million and $0.6 million at December 31, 2022 and 2021, respectively. Actual product returns have not differed materially from estimated amounts recorded in the accompanying consolidated financial statements.

Warranty Reserve

The Company generally provides a four-year warranty on its insulin pumps to end-user customers and may replace any pumps that do not function as intended in accordance with the product specifications within the warranty period. Additionally, the Company offers a six-month warranty on disposable insulin cartridges and infusion sets. Estimated warranty costs are recorded at the time of shipment, and the Company reevaluates the estimate of the warranty reserve obligation at each reporting period. Warranty costs are estimated primarily based on the current expected product replacement cost and expected replacement rates utilizing historical experience. Insulin pumps returned to the Company may be refurbished and redeployed. Experience has shown that initial data for any given pump version may be insufficient; therefore, the Company’s process relies on long-term historical averages until sufficient data are available. As actual experience becomes available, the Company uses the data to update the historical averages. The Company may make further adjustments to the warranty reserve when deemed appropriate, giving additional consideration to revised future expectations of performance based on enhanced hardware components, or new features and capabilities that may become available through Tandem Device Updater. Warranty expense is recorded as a component of cost of sales in the consolidated statements of operations.

The following table provides a reconciliation of the changes in product warranty liabilities for the years ended months ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of the period		$	30,401	$	22,075	$	16,724
Provision for warranties issued during the period		32,699		27,604		21,135
Settlements made during the period		(25,447)		(18,768)		(13,736)
Decreases in warranty estimates		(1,116)		(510)		(2,048)
Balance at end of the period		$	36,537	$	30,401	$	22,075

As of December 31, 2022 and December 31, 2021, total product warranty reserves were included in the following consolidated balance sheet accounts (in thousands):


	December 31, 2022		December 31, 2021

Other current liabilities	$	17,280	$	13,076
Other long-term liabilities	19,257		17,325
Total warranty reserve	$	36,537	$	30,401

Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award, and the portion that is ultimately expected to vest is recognized as compensation expense over the requisite service period on a straight-line basis. The Company estimates the fair value of stock options issued under the Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) and the fair value of the employees’ purchase rights under the Company’s 2013 Employee Stock Purchase Plan (ESPP) using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, including stock price volatility, expected term, dividend yield and risk-free interest rate (see Note 8, “Stockholders’ Equity”). The fair value of restricted stock unit (RSU) awards issued under the 2013 Plan that vest solely based on service is estimated based on the fair market value of the underlying stock on the date of grant. The fair value of RSU awards issued under the 2013 Plan that vest based upon the Company’s actual performance relative to predefined performance metrics, and the awardee’s continuing service through the measurement date, is estimated based on the fair market value of the underlying stock on the date of grant and the probability that the specified performance criteria will be met. At each reporting period, the Company reassesses the probability of the achievement of such performance metrics. Any expense change resulting from an adjustment in the estimated shares to be released is recorded in the period of adjustment.

Shipping and Handling Expenses

Shipping and handling expenses associated with product delivery are included within cost of sales in the Company’s statements of operations. Amounts billed to a customer for shipping and handling are reported as revenues.

Research and Development Costs

All research and development costs are charged to expense as incurred. Such costs include personnel-related costs, including stock-based compensation, supplies, license fees, development prototypes, outside design and testing services, depreciation, allocated facilities and information services, clinical trial costs, milestone payments under the Company’s licensing, development and commercialization agreements, and other indirect costs.

Acquired In-Process Research and Development Expenses

Acquired in-process research and development (IPR&D) expenses reflect the costs of externally developed IPR&D projects acquired directly in a transaction other than a business combination that do not have an alternative future use, including the initial costs of rights to IPR&D projects. The acquired IPR&D is expensed on acquisition date. Future costs to develop these IPR&D projects are recorded in research and development expenses on the consolidated statements of operations as incurred.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets or liabilities are recognized based on the temporary differences between financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Tax law and rate changes are reflected in income in the period such changes are enacted. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.

The Company’s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions using a two-step approach. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. The Company includes interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.

Comprehensive Income (Loss)

All components of comprehensive income (loss), including net income (loss), are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.

Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing the net income or loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net income (loss) per share reflects the potential dilution that would occur if securities exercisable for or convertible into common stock were exercised for or converted into common stock. Dilutive common share equivalents are comprised of stock options and unvested RSUs outstanding under the Company’s stock plans, potential awards to be granted pursuant to the ESPP, and common stock warrants, each calculated using the treasury stock method; and shares issuable upon conversion of the convertible senior notes calculated using the if-converted method.

For the years ended December 31, 2022, 2021 and 2020, the numerator and denominator of the diluted net income (loss) per share computation were calculated as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Net income (loss) - basic and diluted	$	(94,594)	$	15,566	$	(34,382)



Weighted average shares outstanding - basic	64,146		63,000		60,990
Dilutive common share equivalents:
Options to purchase common stock	—		1,129		—
Unvested restricted stock units	—		62		—
Warrants to purchase common stock	—		157		—
Awards to be granted under the ESPP	—		1		—

Weighted average shares outstanding - diluted	64,146		64,349		60,990


	Year Ended December 31,
		2022	2021	2020
Options to purchase common stock		1,138	3,124	5,021
Unvested restricted stock units		1,118	—	78
Warrants to purchase common stock		194	1	379
Awards granted under the ESPP		8	—	3
Convertible senior notes (if-converted)		2,554	2,554	1,605
		5,012	5,679	7,086

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits Employee 401(k) Plan The Company has a defined contribution 401(k) plan for employees in the United States who are at least 18 years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar month following their date of hire. Unless they affirmatively elect otherwise, employees are automatically enrolled in the plan following 30 days from date of rehire or entry date. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, and the Company may elect to match a discretionary percentage of employee contributions. The total amount contributed by the Company to the 401(k) plan was $4.2 million for the year ended December 31, 2022. The Company did not provide a matching contribution prior to 2022.

Stockholders' Equity -Shares of Common Stock Reserved for Future Issuance (Detail) shares in Thousands	Dec. 31, 2022 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	10,096
Shares reserved for issuance upon conversion of Convertible Senior Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	2,554
Shares underlying outstanding warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	194
Shares underlying outstanding stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	4,442
Shares underlying unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,834
Shares authorized for issuance pursuant to awards granted under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	953
Shares authorized for future equity award grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	119

Fourth Quarter Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2022

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information

The financial information for the three months ended December 31, 2022 and 2021 presented in the following table reflects all normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results of the interim periods (in thousands, except per share data):


	For the Quarter Ended
	December 31, 2022		December 31, 2021
Sales	$	220,502	$	209,996
Gross profit	$	115,523	$	113,729
Operating expenses	$	133,300	$	100,991
Operating income (loss)	$	(17,777)	$	12,738
Net income (loss)	$	(15,852)	$	10,808
Basic net income (loss) per share	$	(0.25)	$	0.17
Diluted net income (loss) per share	$	(0.25)	$	0.16

The numerator and denominator of the basic and diluted net income per share computations are calculated as follows for the three months ended December 31, 2022 and 2021 (in thousands):


	For the Quarter Ended
	December 31, 2022		December 31, 2021
Net income (loss) - basic	$	(15,853)	$	10,808
Less: change in fair value of common stock warrants	—		32
Net income (loss) - diluted	$	(15,853)	$	10,840

Weighted average shares outstanding - basic	64,384		63,650
Dilutive common share equivalents:
Options to purchase common stock	—		1,877
Unvested restricted stock units	—		227
Warrants to purchase common stock	—		170
Awards to be granted under the ESPP	—		3

Weighted average shares outstanding - diluted	64,384		65,927

Summary of Significant Accounting Policies - Additional Information (Detail) SFr in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 CHF (SFr)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Impairment of long-lived assets	$ 0
Equity securities without readily determinable fair value, amount		$ 8,300,000	SFr 8.0
Investment owned at cost					$ 8,100,000
Ownership interest of investment owned					5.00%
Guarantee liability current	6,800,000
Allowance for product returns	500,000			$ 600,000
Accumulated deficit	(729,189,000)			(634,595,000)
Convertible senior notes, net - long-term	$ 283,232,000			281,467,000
Insulin Pump
Summary Of Significant Accounting Policies [Line Items]
Warranty period offered	4 years
Slim cartridges and infusion sets
Summary Of Significant Accounting Policies [Line Items]
Warranty period offered	6 months
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of the assets	3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of the assets	7 years
Convertible senior notes \| Level 2 \| Convertible senior notes
Summary Of Significant Accounting Policies [Line Items]
Convertible senior notes, fair value	$ 260,500,000			$ 430,000,000

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Components of Deferred Tax Assets [Abstract]
Net operating loss (NOL) carryforwards	$ 54,598	$ 78,961
Research and development tax credits carryforwards	22,400	16,761
Capitalized research and development expenses	29,760	5,135
Accrued compensation	34,378	28,970
Lease liabilities	32,738	8,012
Other	20,927	20,608
Total deferred tax assets	194,801	158,447
Components of Deferred Tax Liabilities [Abstract]
Operating lease right-of-use assets	(26,505)	(6,637)
Fixed assets	(4,467)	(3,847)
Other	(1,103)	(1,540)
Total deferred tax liabilities	(32,075)	(12,024)
Less valuation allowance	(162,726)	(146,423)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Gross unrecognized tax benefits at the beginning of the year	$ 13,589	$ 10,107	$ 6,580
Increases related to current year positions	3,403	3,482	2,234
Increases (decreases) related to prior year positions	(6)
Increases (decreases) related to prior year positions		0	1,293
Gross unrecognized tax benefits at the end of the year	$ 16,986	$ 13,589	$ 10,107

Debt (Tables)

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Schedule of Convertible Notes

The net carrying amount of the Notes on the consolidated balance sheets consisted of the following (in thousands):


	December 31, 2022		December 31, 2021
Principal amount	$	287,500	$	287,500
Unamortized debt issuance costs	(4,268)		(6,033)
Net carrying amount	$	283,232	$	281,467

Schedule of Interest Expense Recognized

The following table details interest expense related to the Notes recognized for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Contractual interest expense		$	4,313	$	4,313	$	2,707
Amortization of debt issuance costs		1,896		1,727		652
Amortization of debt discount (1)		N/A		N/A		9,446
Total interest expense		$	6,209	$	6,040	$	12,805

(1) The debt discount was reversed upon the adoption of ASU No. 2020-06.

Schedule of Line of Credit

As of December 31, 2022, the Company’s outstanding borrowings and available balance under the Line of Credit were as follows (in millions):


Maximum principal borrowing amount	$	100.0
Less:
Outstanding borrowings	—
Outstanding letters of credit	4.9
Total available balance	$	95.1

Fourth Quarter Financial Data (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Sales	$ 220,502	$ 209,996	$ 801,217	$ 702,799	$ 498,830
Gross profit	115,523	113,729	412,986	376,215	260,520
Operating expenses	133,300	100,991	505,834	353,562	268,477
Operating income (loss)	(17,777)	12,738	(92,848)	22,653	(7,957)
Net income (loss)	$ (15,852)	$ 10,808	$ (94,594)	$ 15,566	$ (34,382)
Basic net income (loss) per share (in dollars per share)	$ (0.25)	$ 0.17	$ (1.47)	$ 0.25	$ (0.56)
Diluted net income (loss) per share (in dollars per share)	$ (0.25)	$ 0.16	$ (1.47)	$ 0.24	$ (0.56)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Leases - Lease Cost, Lease Term Discount Rate, Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 18,432	$ 8,627	$ 7,514
Loss on lease termination and right-of-use asset impairment charge	5,699	0	0
Short-term lease cost	142	90	219
Total lease cost	$ 24,273	$ 8,717	$ 7,733
Weighted-average remaining lease term (in years)	10 years 9 months 18 days	5 years
Weighted-average discount rate used to determine operating lease liabilities	5.30%	5.60%

Composition of Certain Financial Statement Items

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Items

Accounts Receivable

Accounts receivable, net consisted of the following at December 31, 2022 and December 31, 2021 (in thousands):


	December 31,
	2022		2021

Accounts receivable	$	119,044	$	114,974
Less: allowance for credit losses	(4,327)		(4,249)
Accounts receivable, net	$	114,717	$	110,725

Allowance for Credit Losses

The following table provides a reconciliation of the changes in the allowance for estimated accounts receivable credit losses for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of the period		$	4,249	$	3,857	$	3,304
Provision for expected credit losses		4,782		2,333		3,016
Write-offs and adjustments, net of recoveries		(4,704)		(1,941)		(2,463)
Balance at end of the period		$	4,327	$	4,249	$	3,857

Inventories

Inventories consisted of the following at December 31, 2022 and December 31, 2021 (in thousands):


	December 31,
	2022		2021

Raw materials	$	39,207	$	26,911
Work-in-process	18,571		16,612
Finished goods	53,339		25,028
Total inventories	$	111,117	$	68,551

Property and Equipment

Property and equipment, net consisted of the following at (in thousands):


	December 31,
	2022		2021
Leasehold improvements	$	35,828	$	25,245
Office furniture and equipment	13,772		9,943
Computer equipment and software	12,330		11,544
Manufacturing and scientific equipment	62,797		52,823
Total cost	124,727		99,555
Less: accumulated depreciation and amortization	(56,175)		(49,169)
Total property and equipment, net	$	68,552	$	50,386

Depreciation and amortization expense related to property and equipment was $12.3 million, $11.7 million, and $9.2 million for the years ended December 31, 2022, 2021, and 2020, respectively.

Intangible Assets Subject to Amortization

Intangible assets subject to amortization consist of technology-based intangibles related to the Company’s acquisition of Sugarmate, as well as patents purchased or licensed that are related to the Company’s commercialized products. Intangible assets at December 31, 2022 and 2021, which were included in other long-term assets on the consolidated balance sheets, were as follows (in thousands):


	December 31,
	2022		2021
Intangible assets, gross amount	$	12,502	$	12,502
Accumulated amortization	(7,875)		(5,866)
Intangible assets, net	$	4,627	$	6,636
Weighted average remaining amortization period (in months)	30		41

Amortization expense related to intangible assets subject to amortization amounted to $2.0 million, $2.2 million and $1.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The amortization expense is recorded in cost of sales and selling, general and administrative expense in the consolidated statement of operations. The estimated aggregate amortization expense for each of the three succeeding years is $1.9 million for 2023, $1.9 million for 2024, and the remaining $0.9 million in 2025, all of which will be recorded in selling, general and administrative expense in the consolidated statement of operations

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net income (loss)	$ (94,594)	$ 15,566	$ (34,382)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense	14,330	13,845	10,451
Amortization of debt discount and issuance costs	1,896	1,727	10,096
Provision for expected credit losses	4,782	2,333	3,016
Lease termination and impairment charges	7,567	0	0
Change in fair value of common stock warrants	(147)	1,386	17,087
Amortization of premium (discount) on short-term investments	4,187	365	(1,296)
Benefit for deferred income taxes	0	0	(2,126)
Stock-based compensation expense	84,918	60,752	58,431
Acquired in-process research and development expenses	31,039	0	0
Other	1,135	1,013	(19)
Changes in operating assets and liabilities:
Accounts receivable, net	(7,830)	(30,980)	(38,837)
Inventories	(42,452)	(4,954)	(15,361)
Prepaid and other current assets	(58)	(1,570)	(2,427)
Other long-term assets	(1,207)	1,313	129
Accounts payable	24,493	10,275	1,118
Accrued expenses	(461)	4,640	(3,256)
Employee-related liabilities	(12,869)	17,399	5,339
Deferred revenue	8,358	10,611	7,029
Operating leases and other current liabilities	25,445	6,217	5,789
Other long-term liabilities	1,932	1,421	3,888
Net cash provided by operating activities	50,464	111,359	24,669
Investing Activities
Purchases of short-term investments	(467,652)	(733,388)	(497,076)
Proceeds from maturities and redemptions of short-term investments	569,492	570,023	233,314
Purchases of property and equipment	(34,097)	(14,180)	(27,408)
Acquisition, including in-process research and development, net of cash acquired	(25,720)	0	0
Purchases of intangible assets and strategic investments	(8,855)	(9,331)	(4,886)
Net cash provided by (used in) investing activities	33,168	(186,876)	(296,056)
Financing Activities
Proceeds from issuance of convertible senior notes, net of $8,809 debt issuance costs	0	0	278,691
Payment for capped call transactions related to convertible senior notes	0	0	(34,069)
Proceeds from issuance of common stock under Company stock plans, net	17,469	51,340	66,866
Proceeds from exercise of common stock warrants	83	592	2,950
Other financing activities	(675)	0	0
Net cash provided by financing activities	16,877	51,932	314,438
Effect of foreign exchange rate changes on cash	827	153	387
Net increase (decrease) in cash and cash equivalents	101,336	(23,432)	43,438
Cash and cash equivalents at beginning of period	71,181	94,613	51,175
Cash and cash equivalents at end of period	172,517	71,181	94,613
Supplemental disclosures of cash flow information
Interest paid	4,313	4,313	2,707
Income taxes paid	411	260	177
Supplemental schedule of non-cash investing and financing activities
Operating lease right-of-use assets obtained in exchange for operating lease obligations	114,003	15,191	11,022
Purchase of property and equipment included in accounts payable	4,237	1,034	1,082
Intangible costs in accounts payable and other long-term liabilities	$ 515	$ 1,029	$ 2,244

Summary of Significant Accounting Policies - Reconciliation of Change in Estimated Warranty Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of the period	$ 30,401	$ 22,075	$ 16,724
Provision for warranties issued during the period	32,699	27,604	21,135
Settlements made during the period	(25,447)	(18,768)	(13,736)
Decreases in warranty estimates	(1,116)	(510)	(2,048)
Balance at end of the period	36,537	30,401	22,075
Other current liabilities	17,280	13,076
Other long-term liabilities	19,257	17,325
Total warranty reserve	$ 36,537	$ 30,401	$ 22,075

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 172,517	$ 71,181
Short-term investments	444,384	552,630
Accounts receivable, net	114,717	110,725
Inventories	111,117	68,551
Prepaid and other current assets	7,241	8,433
Total current assets	849,976	811,520
Property and equipment, net	68,552	50,386
Operating lease right-of-use assets	110,626	27,503
Other long-term assets	23,631	15,728
Total assets	1,052,785	905,137
Current liabilities:
Accounts payable	55,730	28,032
Accrued expenses	9,595	9,419
Employee-related liabilities	38,682	51,556
Operating lease liabilities	13,121	9,279
Deferred revenue	18,837	10,182
Other current liabilities	29,325	23,388
Total current liabilities	165,290	131,856
Convertible senior notes, net - long-term	283,232	281,467
Operating lease liabilities - long-term	123,524	23,922
Deferred revenue - long-term	16,874	16,940
Other long-term liabilities	23,918	17,840
Total liabilities	612,838	472,025
Commitments and contingencies (Note 13)	0	0
Stockholders’ equity:
Common stock, $0.001 par value; 200,000 shares authorized, 64,513 and 63,833 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.	65	64
Additional paid-in capital	1,170,888	1,068,259
Accumulated other comprehensive loss	(1,817)	(616)
Accumulated deficit	(729,189)	(634,595)
Total stockholders’ equity	439,947	433,112
Total liabilities and stockholders’ equity	$ 1,052,785	$ 905,137

Fourth Quarter Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2022

Quarterly Financial Information Disclosure [Abstract]

Fourth Quarter Financial Data (Unaudited)


	For the Quarter Ended
	December 31, 2022		December 31, 2021
Sales	$	220,502	$	209,996
Gross profit	$	115,523	$	113,729
Operating expenses	$	133,300	$	100,991
Operating income (loss)	$	(17,777)	$	12,738
Net income (loss)	$	(15,852)	$	10,808
Basic net income (loss) per share	$	(0.25)	$	0.17
Diluted net income (loss) per share	$	(0.25)	$	0.16

The numerator and denominator of the basic and diluted net income per share computations are calculated as follows for the three months ended December 31, 2022 and 2021 (in thousands):


	For the Quarter Ended
	December 31, 2022		December 31, 2021
Net income (loss) - basic	$	(15,853)	$	10,808
Less: change in fair value of common stock warrants	—		32
Net income (loss) - diluted	$	(15,853)	$	10,840

Weighted average shares outstanding - basic	64,384		63,650
Dilutive common share equivalents:
Options to purchase common stock	—		1,877
Unvested restricted stock units	—		227
Warrants to purchase common stock	—		170
Awards to be granted under the ESPP	—		3

Weighted average shares outstanding - diluted	64,384		65,927

Short-Term Investments - Contractual Maturities of Available - For- Sale Debt Securities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	$ 404,438
One to Two Years	39,946
Estimated Fair Value	444,384
U.S. Treasury securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	202,855
One to Two Years	8,306
Estimated Fair Value	211,161
Commercial paper
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	112,610
One to Two Years	0
Estimated Fair Value	112,610
U.S. Government-sponsored enterprises
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	73,292
One to Two Years	26,716
Estimated Fair Value	100,008
Corporate debt securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	13,190
One to Two Years	4,924
Estimated Fair Value	18,114
Supranational bonds
Cash Cash Equivalents And Short Term Investments [Line Items]
Within One Year	2,491
One to Two Years	0
Estimated Fair Value	$ 2,491

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation The Company Tandem Diabetes Care, Inc. is a medical device company focused on the design, development and commercialization of technology solutions for people living with diabetes. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the United States, Canada and the Netherlands. The Company manufactures, sells, and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which has an advanced algorithm for managing insulin delivery, and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect mobile app and cloud-based diabetes management application (t:connect), and the Tandem Device Updater, a Mac- and PC-compatible tool which offers and supports remote updates of the Company’s insulin pump software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body. Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the United States, Canada, and the Netherlands. All significant intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company’s foreign subsidiaries is their respective local currency. The Company translates the financial statements of its foreign subsidiaries into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive income (loss), and in accumulated other comprehensive income (loss) in the stockholders’ equity section of the Company’s consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s consolidated statements of operations. Reclassifications Deferred revenue long-term, which was reported as a component of other long-term liabilities in 2021, is now separately reported on the consolidated balance sheet. The Company also reclassified the 2021 liability of $0.1 million related to common stock warrants (see Note 5, “Fair Value Measurements”), which was previously reported separately, to other current liabilities on the Company’s consolidated balance sheet. In addition, certain prior year balances on the consolidated statements of cash flows have been reclassified to conform to the current year presentation.

Fair Value Measurements - Assumptions Used to Estimate Fair Values of Common Stock Warrants (Detail) - Series A Warrants	Dec. 31, 2021
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.003
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.0
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.391
Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	9 months 18 days

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Dec. 31, 2022	Feb. 17, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36189
Entity Registrant Name	Tandem Diabetes Care, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-4327508
Entity Address, Address Line One	11075 Roselle Street
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	366-6900
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TNDM
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 3.8
Entity Common Stock, Shares Outstanding (in shares)		64,528,059
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement on Schedule 14A for the 2023 Annual Meeting of Stockholders, or of an amendment to this Form 10-K, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference in Part III, Items 10-14 of this Form 10-K.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001438133

Debt - Additional Information (Details)		1 Months Ended	12 Months Ended
Debt - Additional Information (Details)	May 18, 2022 USD ($)	May 31, 2020 USD ($) trading_day $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)	May 12, 2020 $ / shares
Debt Instrument [Line Items]
Accumulated deficit			$ (729,189,000)	$ (634,595,000)
Convertible senior notes, net - long-term			283,232,000	281,467,000
Unamortized debt issuance costs						$ 8,809,000
Accounting Standards Update 2020-06 \| Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Accumulated deficit					$ 9,000,000
Additional paid in capital					(85,800,000)
Convertible senior notes, net - long-term					$ 76,800,000
Line of Credit \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term	3 years
Line of credit facility, maximum borrowing capacity	$ 100,000,000		100,000,000.0
Line of Credit \| Letter of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 15,000,000
Line of Credit \| Minimum \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, credit spread on variable rate	0.10%
Commitment fee percentage	0.20%
Line of Credit \| Minimum \| Revolving Credit Facility \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.25%
Line of Credit \| Maximum \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, credit spread on variable rate	0.25%
Commitment fee percentage	0.35%
Line of Credit \| Maximum \| Revolving Credit Facility \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%
Convertible senior notes \| Convertible senior notes
Debt Instrument [Line Items]
Principal		$ 287,500,000	287,500,000	287,500,000
Interest rate		1.50%
Net proceeds from issuance of convertible notes		$ 244,600,000
Debt instrument, convertible, conversion ratio		0.0088836
Conversion price (in dollars per share) \| $ / shares		$ 112.57
Debt instrument, convertible, threshold trading days \| trading_day		20
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day		30
Redemption price percentage		100.00%
Principal amount			0	96,900,000
Unamortized debt issuance costs			$ 4,268,000	$ 6,033,000
Effective interest rate			2.20%
Remaining debt term			2 years 3 months 18 days
Capped call transactions net cost		$ 34,100,000
Debt instrument, initial cap price per share (in dollars per share) \| $ / shares		$ 173.18
Stock price per share (in dollars per share) \| $ / shares							$ 86.59
Convertible senior notes \| Convertible senior notes \| Minimum
Debt Instrument [Line Items]
Conversion price (in dollars per share) \| $ / shares		$ 112.57
Debt instrument, convertible, threshold percentage of stock price trigger		130.00%
Convertible senior notes \| Convertible senior notes \| Maximum
Debt Instrument [Line Items]
Conversion price (in dollars per share) \| $ / shares		$ 173.18
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 130%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| trading_day		20
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day		30
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 130% \| Minimum
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger		130.00%
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 98%
Debt Instrument [Line Items]
Debt instrument, convertible, threshold trading days \| trading_day		5
Debt instrument, convertible, threshold trading days consecutive trading days \| trading_day		5
Convertible senior notes \| Convertible senior notes \| Conversion Instance, 98% \| Minimum
Debt Instrument [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger		98.00%

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Sales	$ 801,217	$ 702,799	$ 498,830
Cost of sales	388,231	326,584	238,310
Gross profit	412,986	376,215	260,520
Operating expenses:
Selling, general and administrative	335,681	261,508	204,903
Research and development	139,114	92,054	63,574
Acquired in-process research and development expenses	31,039	0	0
Total operating expenses	505,834	353,562	268,477
Operating income (loss)	(92,848)	22,653	(7,957)
Other income (expense), net:
Interest income and other, net	6,057	674	1,567
Interest expense	(6,208)	(6,040)	(12,805)
Change in fair value of common stock warrants	147	(1,386)	(17,087)
Total other expense, net	(4)	(6,752)	(28,325)
Income (loss) before income taxes	(92,852)	15,901	(36,282)
Income tax expense (benefit)	1,742	335	(1,900)
Net income (loss)	(94,594)	15,566	(34,382)
Other comprehensive income (loss):
Unrealized loss on short-term investments	(2,233)	(693)	(20)
Foreign currency translation gains (losses)	1,032	(143)	118
Comprehensive income (loss)	$ (95,795)	$ 14,730	$ (34,284)
Net income (loss) per share - basic (in dollars per share)	$ (1.47)	$ 0.25	$ (0.56)
Net income (loss) per share - diluted (in dollars per share)	$ (1.47)	$ 0.24	$ (0.56)
Weighted average shares used to compute basic net income (loss) per share (in shares)	64,146	63,000	60,990
Weighted average shares used to compute diluted net income (loss) per share (in shares)	64,146	64,349	60,990

Composition of Certain Financial Statement Items - Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 39,207	$ 26,911
Work-in-process	18,571	16,612
Finished goods	53,339	25,028
Total inventories	$ 111,117	$ 68,551

Organization and Basis of Presentation (Policies)	12 Months Ended
Organization and Basis of Presentation (Policies)	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	The Company Tandem Diabetes Care, Inc. is a medical device company focused on the design, development and commercialization of technology solutions for people living with diabetes. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries in the United States, Canada and the Netherlands. The Company manufactures, sells, and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which has an advanced algorithm for managing insulin delivery, and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with other complementary digital health offerings, such as the t:connect mobile app and cloud-based diabetes management application (t:connect), and the Tandem Device Updater, a Mac- and PC-compatible tool which offers and supports remote updates of the Company’s insulin pump software from a personal computer. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The statements include the accounts of Tandem Diabetes Care, Inc. and its wholly-owned subsidiaries in the United States, Canada, and the Netherlands. All significant intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company’s foreign subsidiaries is their respective local currency. The Company translates the financial statements of its foreign subsidiaries into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in other comprehensive income (loss), and in accumulated other comprehensive income (loss) in the stockholders’ equity section of the Company’s consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest income and other, net in the Company’s consolidated statements of operations.
Reclassifications	Reclassifications Deferred revenue long-term, which was reported as a component of other long-term liabilities in 2021, is now separately reported on the consolidated balance sheet. The Company also reclassified the 2021 liability of $0.1 million related to common stock warrants (see Note 5, “Fair Value Measurements”), which was previously reported separately, to other current liabilities on the Company’s consolidated balance sheet. In addition, certain prior year balances on the consolidated statements of cash flows have been reclassified to conform to the current year presentation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty to be cash equivalents.
Short-Term Investments	Short-Term Investments The Company’s short-term investments are classified as available-for-sale securities. Such securities are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. The Company’s short-term investments consist of Level 1 and Level 2 financial instruments in the fair value hierarchy. The net unrealized gains or losses on available-for-sale securities that are not related to credit factors are reported as a component of other comprehensive income (loss) within the statements of operations and accumulated other comprehensive income (loss) as a separate component of stockholders’ equity on the consolidated balance sheets. The Company determines realized gains or losses on the sale of available-for-sale securities using the specific identification method and includes net realized gains and losses as a component of other income or expense within the consolidated statements of operations. The Company reviews its available-for-sale debt securities for credit losses quarterly, considering a variety of factors, including the significance of the decline in value as compared to the amortized cost basis; underlying factors contributing to a decline in the prices of securities in a single asset class; the security’s relative performance versus its peers, sector or asset class; the market and economy in general; views of external investment managers; news or financial information that has been released specific to the investee; and the outlook for the overall industry in which the investee operates. Losses on available-for-sale debt securities as a result of credit factors are recognized by recording an impairment loss as a component of other income or expense within the consolidated statements of operations and a corresponding allowance for credit losses. The Company has not recognized any impairment losses related to its short-term investments during the years ended December 31, 2022, 2021 and 2020.
Accounts Receivable	Accounts Receivable The Company grants credit to various customers in the ordinary course of business and is paid directly by customers who use its products, distributors and third-party insurance payors. The Company maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, forecasts about the future, and various assumptions and estimates that are believed to be reasonable under the circumstances, including credit risks as a result of the coronavirus pandemic, recessionary concerns, changes in discretionary spending, increased interest rates, and other macroeconomic factors. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains deposit accounts in federally insured financial institutions in excess of federally insured limits. The Company also maintains investments in money market funds that are not federally insured. Additionally, the Company has established guidelines regarding investment instruments and their maturities, which are designed to maintain preservation of principal and liquidity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and employee-related liabilities are reasonable estimates of their fair values because of the short-term nature of these assets and liabilities. Short-term investments are carried at fair value. The carrying value and estimated fair value of certain of the Company’s common stock warrants was determined using the Black-Scholes pricing model as of December 31, 2021 (see Note 5, “Fair Value Measurements”). The Company’s convertible senior notes are carried at amortized cost on the consolidated balance sheets (see Note 7, “Debt”). The Company measures the fair value of its convertible senior notes for disclosure purposes. The Company estimated the fair value of its convertible senior notes to be $260.5 million and $430.0 million at December 31, 2022 and December 31, 2021, respectively, based on Level 2 quoted market prices as of those dates
Valuation of Inventories	Valuation of Inventories Inventories are valued at the lower of cost or net realizable value, determined by the first-in, first-out method. Inventory is recorded using standard cost, including material, labor and overhead costs. The Company periodically reviews inventories for potential impairment and adjusts inventory for potentially excess or obsolete goods to state inventories at their net realizable value. Factors influencing these adjustments include quantities on hand and firm purchase commitments, expectations of future use, judgments based on quality control testing data and assessments of the likelihood of scrapping or obsoleting certain inventories based on future demand for its products and market conditions.
Long-Lived Assets	Long-Lived Assets Property and Equipment Property and equipment, which primarily consist of office furniture and equipment, manufacturing equipment, scientific equipment, computer equipment, and leasehold improvements, are stated at cost, less accumulated depreciation. Property and equipment are depreciated over the estimated useful lives of the assets, generally three to seven years, using the straight-line method. Leasehold improvements and related equipment are amortized over the lesser of the estimated useful lives of the assets or the remaining lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised. Maintenance and repair costs are expensed as incurred.
Operating Lease Right-of-Use Assets and Liabilities	Operating Lease Right-of-Use Assets and Liabilities Operating lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. For lease agreements entered into or reassessed after the adoption of ASC 842 Leases, the Company combines lease and non-lease components. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the Company’s consolidated balance sheets. Landlord improvement allowances and other similar lease incentives are recorded as a reduction of the right-of-use leased assets, and are amortized on a straight-line basis as a reduction to operating lease costs.
Intangible Assets Subject to Amortization	Intangible Assets Subject to AmortizationFinite-lived intangible assets (see Note 4, “Composition of Certain Financial Statement Items”) are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is recognized over their estimated useful lives on a straight-line basis.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, right-of-use lease assets, and acquired intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined using unobservable (Level 3) inputs, including discounted cash flow models, future estimated sublease income, and third-party independent appraisals, as considered necessary. There is uncertainty in the projected undiscounted future cash flows used in the Company’s impairment review analysis, which requires the use of estimates and assumptions. If actual performance does not achieve the projections, or if the assumptions used change in the future, the Company may be required to recognize additional impairment charges in future periods. Other than the impairment of operating lease right-of-use assets recognized in the fourth quarter of 2022 (see Note 6, “Leases”), there were no impairments of long-lived assets, including acquired intangible assets, during the years ended December 31, 2022 and 2021.
Strategic Investments	Strategic Investments During the third quarter of 2022, the Company made an investment of Swiss Francs (“CHF”) 8.0 million, or $8.3 million, in AMF Medical SA (“AMF Medical”), a privately held company. The investment is included as a component of other long-term assets on the consolidated balance sheet at December 31, 2022. On January 19, 2023, the Company completed the acquisition of AMF Medical, pursuant to the terms of the Purchase Agreement entered into on December 13, 2022 (see Note 15, “Subsequent Event”). During the second quarter of 2021, the Company made an $8.1 million equity investment in a private company, which represented less than 5% of the outstanding equity of that company as of the date of investment. The investment is carried at cost minus impairment, if any, adjusted for changes in observable prices and is included as a component of other long-term assets on the consolidated balance sheets. The Company monitors this investment to evaluate whether any increase or decline in its value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions
Revenue Recognition	Revenue Recognition Revenue is generated primarily from sales of insulin pumps, disposable insulin cartridges and infusion sets to individual customers with third-party insurance coverage and through a network of distributors that resell the products to insulin-dependent diabetes customers. The Company recognizes revenue when it transfers control of the promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, net of estimated returns. Revenue Recognition for Arrangements with Multiple Performance Obligations The Company considers the individual deliverables in its product offering as separate performance obligations. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company allocates the consideration to the individual performance obligations and recognizes the consideration based on when the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. Generally, insulin pumps, cartridges, infusion sets, and accessories are deemed performance obligations that are satisfied at a point in time when the customer obtains control of the promised good, which typically is upon shipment for our distributor arrangements and upon receipt for sales directly to individual customers. Complementary products, such as t:connect and the Tandem Device Updater, are considered distinct performance obligations that are satisfied over time, as access and support for these products is provided throughout the typical four-year warranty period of the insulin pumps. Accordingly, revenue related to the complementary products is deferred and recognized over a four-year period. Where there is no standalone value for the complementary product, the Company determines its value by applying the expected cost plus a margin approach and then allocates the residual to the insulin pumps. Tandem Choice Program In September 2022, the Company announced and launched a new technology access program, (Tandem Choice) that provides eligible, in-warranty t:slim X2 customers in the United States with the flexibility to obtain the newest hardware platform when it is commercially available. Participating customers have the right to purchase the alternative Tandem pump for a fee (the Choice Right). The Tandem Choice expires on December 31, 2024. For purposes of evaluating the Tandem Choice, in accordance with ASC 606, the Company has determined that the ability for a customer to upgrade to a new technology, represents a material right because the pricing inherent in such option provides the customer with a discount that is incremental to the range of discounts that would otherwise be granted for the related goods and services to comparable customers. The standalone selling price for the Choice Right was estimated based on the adjusted market assessment approach and contemplates the likelihood that the respective option will be exercised. Sales ReturnsThe Company offers a 90-day right of return to customers in the U.S. and Canada from the date of shipment of its insulin pumps, provided a physician’s confirmation of the medical reason for the return is received. Estimated allowances for sales returns are based on historical returned quantities as compared to pump shipments in those same periods of return, adjusted for known or expected changes in the marketplace when appropriate. Shipping and Handling Expenses Shipping and handling expenses associated with product delivery are included within cost of sales in the Company’s statements of operations. Amounts billed to a customer for shipping and handling are reported as revenues.
Warranty Reserve	Warranty Reserve The Company generally provides a four-year warranty on its insulin pumps to end-user customers and may replace any pumps that do not function as intended in accordance with the product specifications within the warranty period. Additionally, the Company offers a six-month warranty on disposable insulin cartridges and infusion sets. Estimated warranty costs are recorded at the time of shipment, and the Company reevaluates the estimate of the warranty reserve obligation at each reporting period. Warranty costs are estimated primarily based on the current expected product replacement cost and expected replacement rates utilizing historical experience. Insulin pumps returned to the Company may be refurbished and redeployed. Experience has shown that initial data for any given pump version may be insufficient; therefore, the Company’s process relies on long-term historical averages until sufficient data are available. As actual experience becomes available, the Company uses the data to update the historical averages. The Company may make further adjustments to the warranty reserve when deemed appropriate, giving additional consideration to revised future expectations of performance based on enhanced hardware components, or new features and capabilities that may become available through Tandem Device Updater. Warranty expense is recorded as a component of cost of sales in the consolidated statements of operations.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award, and the portion that is ultimately expected to vest is recognized as compensation expense over the requisite service period on a straight-line basis. The Company estimates the fair value of stock options issued under the Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan) and the fair value of the employees’ purchase rights under the Company’s 2013 Employee Stock Purchase Plan (ESPP) using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, including stock price volatility, expected term, dividend yield and risk-free interest rate (see Note 8, “Stockholders’ Equity”). The fair value of restricted stock unit (RSU) awards issued under the 2013 Plan that vest solely based on service is estimated based on the fair market value of the underlying stock on the date of grant. The fair value of RSU awards issued under the 2013 Plan that vest based upon the Company’s actual performance relative to predefined performance metrics, and the awardee’s continuing service through the measurement date, is estimated based on the fair market value of the underlying stock on the date of grant and the probability that the specified performance criteria will be met. At each reporting period, the Company reassesses the probability of the achievement of such performance metrics. Any expense change resulting from an adjustment in the estimated shares to be released is recorded in the period of adjustment.
Research and Development Costs	Research and Development Costs All research and development costs are charged to expense as incurred. Such costs include personnel-related costs, including stock-based compensation, supplies, license fees, development prototypes, outside design and testing services, depreciation, allocated facilities and information services, clinical trial costs, milestone payments under the Company’s licensing, development and commercialization agreements, and other indirect costs. Acquired In-Process Research and Development Expenses Acquired in-process research and development (IPR&D) expenses reflect the costs of externally developed IPR&D projects acquired directly in a transaction other than a business combination that do not have an alternative future use, including the initial costs of rights to IPR&D projects. The acquired IPR&D is expensed on acquisition date. Future costs to develop these IPR&D projects are recorded in research and development expenses on the consolidated statements of operations as incurred.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets or liabilities are recognized based on the temporary differences between financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Tax law and rate changes are reflected in income in the period such changes are enacted. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required. The Company’s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions using a two-step approach. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. The Company includes interest and penalties related to income taxes, including unrecognized tax benefits, within income tax expense.
Comprehensive Income (Loss)	Comprehensive Income (Loss) All components of comprehensive income (loss), including net income (loss), are reported in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments.
Net Income (Loss) Per Share	Net Income (Loss) Per ShareBasic net income (loss) per share is calculated by dividing the net income or loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net income (loss) per share reflects the potential dilution that would occur if securities exercisable for or convertible into common stock were exercised for or converted into common stock. Dilutive common share equivalents are comprised of stock options and unvested RSUs outstanding under the Company’s stock plans, potential awards to be granted pursuant to the ESPP, and common stock warrants, each calculated using the treasury stock method; and shares issuable upon conversion of the convertible senior notes calculated using the if-converted method.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable insulin cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as one segment and a single reporting unit because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

Leases - Future Minimum Payments Under Non-cancellable Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2023	$ 13,133
2024	17,198
2025	17,023
2026	17,068
2027	17,333
Thereafter	103,844
Total undiscounted lease payments	185,599
Less: amount representing interest	(48,954)
Present value of operating lease liabilities	136,645
Less: current portion of operating lease liabilities	(13,121)	$ (9,279)
Operating lease liabilities - long-term	$ 123,524	$ 23,922

Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
United States	$ (94,033)	$ 15,211	$ (36,667)
Foreign	1,181	690	385
Income (loss) before income taxes	$ (92,852)	$ 15,901	$ (36,282)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Debt - Line of Credit (Details) - USD ($)	Dec. 31, 2022	May 18, 2022
Line of Credit Facility [Line Items]
Outstanding letters of credit	$ 4,900,000
Line of Credit
Line of Credit Facility [Line Items]
Total available balance	95,100,000
Revolving Credit Facility \| Line of Credit
Line of Credit Facility [Line Items]
Maximum principal borrowing amount	100,000,000.0	$ 100,000,000
Outstanding borrowings	0
Letter of Credit \| Line of Credit
Line of Credit Facility [Line Items]
Maximum principal borrowing amount		$ 15,000,000
Outstanding letters of credit	$ 4,900,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Subsequent Event - Narrative (Details) SFr in Millions, $ in Millions	Jan. 19, 2023 CHF (SFr)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 CHF (SFr)
Subsequent Event [Line Items]
Equity securities without readily determinable fair value, amount		$ 8.3	SFr 8.0
AMF Medical Acquisition \| Subsequent Event
Subsequent Event [Line Items]
Payments of cash	SFr 62.4
Additional earnout payment	129.6
AMF Medical Acquisition \| Development Milestones \| Subsequent Event
Subsequent Event [Line Items]
Additional earnout payment	38.4
AMF Medical Acquisition \| Regulatory Clearance Milestone \| Subsequent Event
Subsequent Event [Line Items]
Additional earnout payment	SFr 91.2

Stockholders' Equity - Additional Information (Detail) $ in Millions	1 Months Ended			3 Months Ended		12 Months Ended
	Mar. 31, 2022	Feb. 28, 2022	Oct. 31, 2013 purchase_period	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued by each warrant (in shares)						1
Total stock-based compensation expense capitalized as part of cost of inventory \| $						$ 1.1	$ 1.0
Unrecognized compensation expense \| $						$ 143.9
Share-based payment arrangement, cost not yet recognized, period for recognition						2 years 3 months 18 days
Awards to be granted under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						2 years
Maximum percentage that employee can contribute for purchase of common stock			15.00%
Number of purchase periods \| purchase_period			4
Offering period			2 years
Purchase period			6 months
Purchase of common stock under ESPP (in shares)						262,936	172,694
Proceeds from stock plans \| $						$ 12.7	$ 11.1
Awards to be granted under the ESPP \| Date of Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock on date of purchase			85.00%
Awards to be granted under the ESPP \| Date of Purchase
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock on date of purchase			85.00%
Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term of stock options (in years)						10 years
Vesting period				3 years	4 years
Vesting period of remaining stock (in years)				2 years	3 years
Share-based Payment Arrangement, Option \| Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vested percentage				33.00%	25.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years	4 years
Granted (in shares)						1,542,859	564,034	134,694
RSU vested in period, fair value \| $						$ 12.7	$ 5.1	$ 0.2
Restricted Stock Units (RSUs) \| Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vested percentage	33.00%	25.00%
Restricted Stock Units (RSUs) \| Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years	3 years
Performance-Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						53,662	25,674
Warrants to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issue to purchase common stock (in shares)						5,678	155,517

Debt - Interest Expense Recognized (Details) - Convertible senior notes - Convertible senior notes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 4,313	$ 4,313	$ 2,707
Amortization of debt issuance costs	1,896	1,727	652
Amortization of debt discount			9,446
Total interest expense	$ 6,209	$ 6,040	$ 12,805

Composition of Certain Financial Statement Items - Reconciliation of Change in Estimated Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for doubtful accounts
Balance at beginning of the period	$ 4,249	$ 3,857	$ 3,304
Provision for expected credit losses	4,782	2,333	3,016
Write-offs and adjustments, net of recoveries	(4,704)	(1,941)	(2,463)
Balance at end of the period	$ 4,327	$ 4,249	$ 3,857

Organization and Basis of Presentation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021
Organization And Basis Of Presentation [Line Items]
Increase in other current liabilities		$ 100
Revision of Prior Period, Reclassification, Adjustment
Organization And Basis Of Presentation [Line Items]
Common stock warrants			$ 100
Fair Value, Measurements, Recurring
Organization And Basis Of Presentation [Line Items]
Common stock warrants			$ (147)
Insulin Pump \| Minimum
Organization And Basis Of Presentation [Line Items]
Expected life span term	4 years

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

The Company's leases consist of operating leases for general office space, research and development, manufacturing and warehouse facilities, and equipment. These noncancellable operating leases have initial lease terms from two years to thirteen years. Leases with an initial term of 12 months or less (Short-term Lease) are expensed as incurred and are not recorded as right-of-use leased assets on the Company’s consolidated balance sheets. The Company is required to recognize operating lease right-of-use assets and liabilities, and begin recording lease expense when the Company takes possession of the leased property (the Commencement Date). The Company recognizes lease expense for these leases on a straight-line basis over the lease term. Because the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease Commencement Date to determine the operating lease right-of-use assets and liabilities based on the present value of future lease payments over the lease term. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced before that date.

Certain leases include an option to renew, with renewal terms that can extend the lease term for additional periods. The exercise of lease renewal options is at the Company’s sole discretion. For renewal options that are reasonably certain at the lease Commencement Date of being exercised, the Company includes the renewal option period in the lease term.

Vista Sorrento Lease

In March 2021, the Company entered into a second amendment (Second Amendment) to its lease agreement for office space located on Vista Sorrento Parkway in San Diego, California (Vista Sorrento Lease) covering 59,013 square feet of general administrative office space (Existing Premises). The Second Amendment expanded the Existing Premises by adding 14,916 square feet of general administrative office space (Expansion Space), and extended the lease term for the Existing Premises through January 2028. The Expansion Space lease Commencement Date occurred in March 2021, and the lease term expires in January 2028. The Company has two options to extend the term of the Vista Sorrento Lease, covering both the Existing Premises and the Expansion Space, with each option providing for an additional period of five years. The Vista Sorrento Lease term was determined assuming the renewal options would not be exercised. The Company recognized operating lease right-of-use assets and corresponding operating lease liabilities of $15.1 million on the consolidated balance sheet in the first quarter of 2021 related to the Second Amendment.

Tech Center Lease

In September 2021, the Company entered into a lease agreement for 181,949 square feet of additional general administrative, laboratory, and research and development office space (the Premises) located on High Bluff Drive in San Diego, California (Tech Center Lease). Possession of the Premises is expected to be tendered to the Company by the landlord in two phases, with Phase I consisting of 143,850 rentable square feet, and Phase II consisting of 38,099 rentable square feet. The Company intends to use Phase I of the Tech Center Lease for operations currently occupying 77,458 square feet of leased space, located on Roselle Street in San Diego, California, that is scheduled to expire in May 2023. The Tech Center Lease also includes a first right of offer with respect to an additional 34,569 rentable square feet of general office space should the space become available.

The initial lease term Phase I Commencement Date occurred in March 2022 when the Company was tendered possession of the Phase I portion of the Premises, and rent payments commenced in September 2022 (the Phase I Rent Commencement Date). The Phase II Commencement Date is expected to occur upon the earlier of (i) the date upon which the Company first commences business in the Phase II portion of the Premises, and (ii) May 1, 2025 (the Phase II Rent Commencement Date). The Tech Center Lease term expires in April 2035. The Company has two options to extend the term of the lease, with each option providing for an additional period of five years. The Tech Center Lease term was determined assuming the renewal options would not be exercised.

The initial base rent for the Tech Center Lease is approximately $906,000 per month beginning on the Phase I Rent Commencement Date, and the base rent increases by approximately $255,000 per month on the Phase II Rent Commencement Date. The monthly base rent will increase by 3.0% on each annual anniversary of the respective Rent Commencement Date. In addition to the monthly base rent, the Company is required to pay its proportionate share of certain ongoing operating expenses throughout the duration of the lease. No base rent, other than the proportionate share of operating expenses, will be due for the Phase I portion of the Premises for months two through nine following the Phase I Rent Commencement Date, and for the Phase II portion of the Premises for months two through five following the Phase II Rent Commencement Date. The Company recognized operating lease right-of-use assets and corresponding operating lease liabilities of $107.5 million on the consolidated balance sheet on the Phase I Commencement Date in the first quarter of 2022.

High Bluff Lease

In May 2021, the Company entered into a lease agreement for approximately 31,372 square feet of general office space located on High Bluff Drive, in San Diego, California (High Bluff Lease). The High Bluff Lease is a direct lease agreement for property the Company previously occupied subject to a sublease agreement. The lease term began in April 2022 following the termination of the High Bluff sublease in March 2022, and is scheduled to expire in March 2024. The Company recognized operating lease right-of-use assets and corresponding operating lease liabilities of $3.0 million on the consolidated balance sheet on the Commencement Date in the second quarter of 2022.

Barnes Canyon Lease

In November 2022, the Company exercised its one-time option to extend the term of the lease covering 48,880 square feet of general office, manufacturing and warehouse space located on Barnes Canyon Road in San Diego, California (Barnes Canyon Lease) for an additional five years from November 2023 to November 2028. The Company recognized operating lease right-of-use assets and corresponding operating lease liabilities of $3.0 million on the consolidated balance sheet in the fourth quarter of 2022 related to the Barnes Canyon Lease term extension.

Lease Termination and Impairment Charges

During the fourth quarter of 2022, the Company recorded $12.4 million of lease termination and impairment charges primarily related to our customer and technical support office space in Boise, Idaho. The $12.4 million charge consisted of a $6.7 million loss on disposal of fixed assets, including leasehold improvements, furniture and fixtures, $3.8 million net loss on lease termination, and $1.9 million impairment of operating lease right-of-use assets, and is recorded as a component of selling, general and administrative expenses in the consolidated statement of operations.

Supplemental Lease Disclosure Information

The Company’s lease costs recorded in the consolidated statements of operations were as follows (in thousands):


	Year Ended December 31,
		2022		2021		2020
Operating lease cost		$	18,432	$	8,627	$	7,514
Loss on lease termination and right-of-use asset impairment charge		5,699		—		—
Short-term lease cost		142		90		219
Total lease cost		$	24,273	$	8,717	$	7,733

Maturities of operating lease liabilities at December 31, 2022 were as follows (in thousands):


Years Ending December 31,
2023	$	13,133
2024	17,198
2025	17,023
2026	17,068
2027	17,333
Thereafter	103,844
Total undiscounted lease payments	185,599
Less: amount representing interest	(48,954)
Present value of operating lease liabilities	136,645
Less: current portion of operating lease liabilities	(13,121)
Operating lease liabilities - long-term	$	123,524

The weighted-average remaining lease term and weighted-average discount rate for operating leases were as follows:


	December 31, 2022		December 31, 2021
Weighted-average remaining lease term (in years)	10.8		5.0
Weighted-average discount rate used to determine operating lease liabilities	5.3	%	5.6	%

Cash paid for amounts included in the measurement of lease liabilities, representing operating cash flows from operating leases, was $16.7 million, which included a $4.8 million lease termination payment, $9.5 million, and $8.2 million for the years ended December 31, 2022, 2021, and 2020, respectively.

Lease For Which Accounting Has Not Yet Commenced

As of December 31, 2022, the Commencement Date for Phase II of the Tech Center Lease had not yet occurred. Accordingly, the consolidated balance sheet at December 31, 2022 does not include operating lease right-of-use assets and operating lease liabilities, and the consolidated statement of operations for the year ended December 31, 2022 does not include any lease costs, related to Phase II of the Tech Center Lease. In addition, the above disclosures of the Company’s lease costs, maturities of operating lease liabilities, and the weighted-average remaining lease term and weighted-average discount rate, do not include any amounts related to Phase II of the Tech Center Lease.

The Company currently estimates that Phase II Commencement Date will occur in the first quarter of 2025, at which time the Phase II operating lease right-of-use assets and liabilities will be recorded. Future minimum payments for monthly base rent due under Phase II of the Tech Center Lease, are currently estimated to total $34.7 million from 2025 through 2035, subject to a number of factors, including the actual Commencement Date of Phase II. Because the incremental borrowing rate will not be available until the Phase II Commencement Date, we are not yet able to determine the Phase II operating lease right-of-use assets and liabilities.

Stockholders' Equity - Common Stock Warrants (Details) - Common Stock Warrant Expiring March 2027	Dec. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price (in dollars per share) \| $ / shares	$ 23.50
Outstanding warrants (in shares) \| shares	193,788

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	$ (19,499)	$ 3,339	$ (7,619)
State income tax, net of federal benefit	(926)	(254)	(2,792)
Warrants revaluation	(31)	356	3,588
Research and development credits	(6,263)	(5,703)	(5,330)
Section 382 limitation	0	(97)	1,021
Stock-based compensation	2,282	(7,609)	(18,309)
Officers' compensation	2,931	4,024	2,612
Acquired IPR&D expenses	6,518	0	0
Other	962	124	479
Change in valuation allowance	15,768	6,155	24,450
Income tax expense (benefit)	$ 1,742	$ 335	$ (1,900)

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule of Lease Cost

The Company’s lease costs recorded in the consolidated statements of operations were as follows (in thousands):


	Year Ended December 31,
		2022		2021		2020
Operating lease cost		$	18,432	$	8,627	$	7,514
Loss on lease termination and right-of-use asset impairment charge		5,699		—		—
Short-term lease cost		142		90		219
Total lease cost		$	24,273	$	8,717	$	7,733

The weighted-average remaining lease term and weighted-average discount rate for operating leases were as follows:


	December 31, 2022		December 31, 2021
Weighted-average remaining lease term (in years)	10.8		5.0
Weighted-average discount rate used to determine operating lease liabilities	5.3	%	5.6	%

Schedule of Future Minimum Payments Under Non-cancellable Operating Leases

Maturities of operating lease liabilities at December 31, 2022 were as follows (in thousands):


Years Ending December 31,
2023	$	13,133
2024	17,198
2025	17,023
2026	17,068
2027	17,333
Thereafter	103,844
Total undiscounted lease payments	185,599
Less: amount representing interest	(48,954)
Present value of operating lease liabilities	136,645
Less: current portion of operating lease liabilities	(13,121)
Operating lease liabilities - long-term	$	123,524

Summary of Significant Accounting Policies - Anti-Dilutive Securities (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	5,012	5,679	7,086
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,138	3,124	5,021
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,118	0	78
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	194	1	379
Awards granted under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	8	0	3
Convertible senior notes (if-converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,554	2,554	1,605

Leases - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
Leases - Additional Information (Details) $ in Thousands	May 30, 2025 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2022 USD ($) ft²	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($) extension	Sep. 30, 2021 ft²	May 31, 2021 ft²	Mar. 31, 2021 USD ($) ft² extension
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets			$ 110,626	$ 110,626	$ 27,503
Operating lease, liability			136,645	136,645
Lease termination and impairment charges			12,400	7,567	0	$ 0
Loss on disposition of assets			6,700
Loss on termination of lease			3,800
Operating lease, impairment loss			1,900
Operating lease, payments				16,700	$ 9,500	$ 8,200
Payment of lease termination				4,800
Total future minimum lease payments			$ 185,599	$ 185,599
Vista Sorrento Parkway Lease
Lessee, Lease, Description [Line Items]
Operating lease, number of options to extend \| extension												2
Operating lease extension period												5 years
Operating lease right-of-use assets									$ 107,500			$ 15,100
Operating lease, liability									$ 107,500			$ 15,100
Vista Sorrento Parkway Lease, Existing Premises
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²												59,013
Vista Sorrento Parkway Lease, Expansion Space
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²												14,916
Tech Center Lease
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²										181,949
Operating lease, number of options to extend \| extension									2
Annual percentage increase in monthly base rent		3.00%
Tech Center Lease Phase I
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²			77,458	77,458						143,850
Operating lease extension period									5 years
Monthly base rent		$ 906
Beginning period after initial lease term for which no rent is due		2 months
Ending period for which no rent is due		9 months
Tech Center Lease Phase II
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²										38,099
Total future minimum lease payments			$ 34,700	$ 34,700
Tech Center Lease Phase II \| Forecast
Lessee, Lease, Description [Line Items]
Increase in monthly base rent	$ 255
Beginning period after initial lease term for which no rent is due	2 months
Ending period for which no rent is due	5 months
Tech Center Lease, Additional Space
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²			34,569	34,569
High Bluff Drive Lease
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²											31,372
Operating lease, liability								$ 3,000
Barnes Canyon Lease
Lessee, Lease, Description [Line Items]
Area of office space leased \| ft²							48,880
Operating lease, liability							$ 3,000
Minimum
Lessee, Lease, Description [Line Items]
Lease term			2 years	2 years
Maximum
Lessee, Lease, Description [Line Items]
Lease term			13 years	13 years

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	Dec. 31, 2020 USD ($)
Statement of Cash Flows [Abstract]
Unamortized debt issuance costs	$ 8,809

Income Taxes - Schedule of Components of Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal			$ 216	$ 0	$ 0
State			1,228	174	75
Foreign			298	161	151
Total current tax expense			1,742	335	226
Deferred:
Federal			0	0	(1,760)
State			0	0	(366)
Foreign			0	0	0
Total deferred income tax benefit	$ 0	$ 0	0	0	(2,126)
Income tax expense (benefit)			$ 1,742	$ 335	$ (1,900)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis


	Fair Value Measurements at December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents(1)	$	150,742	$	150,742	$	—	$	—
U.S. Treasury securities	211,161		211,161		—		—
Commercial paper	112,610		—		112,610		—
U.S. Government-sponsored enterprises	100,008		—		100,008		—
Corporate debt securities	18,114		—		18,114		—
Supranational bonds	2,491		—		2,491		—
Total assets	$	595,126	$	361,903	$	233,223	$	—


	Fair Value Measurements at December 31, 2021
	Total		Level 1		Level 2		Level 3
Assets
Cash equivalents(1)	$	48,286	$	48,286	$	—	$	—
U.S. Treasury securities	221,724		221,724		—		—
Commercial paper	218,381		—		218,381		—
U.S. Government-sponsored enterprises	50,686		—		50,686		—
Corporate debt securities	58,836		—		58,836		—
Supranational bonds	3,003		—		3,003		—
Total assets	$	600,916	$	270,010	$	330,906	$	—
Liabilities
Common stock warrants(2)	$	147	$	—	$	—	$	147
Total liabilities	$	147	$	—	$	—	$	147

(1)Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.

(2)Included in other current liabilities on the Company’s consolidated balance sheet.

Schedule of Assumptions Used to Estimate Fair Values of Common Stock Warrants

. The assumptions used to estimate the fair values of the outstanding Series A warrants at December 31, 2021 were as follows:



	December 31, 2021
Risk-free interest rate	0.3	%
Dividend yield	0.0%
Expected volatility	39.1	%
Expected term (in years)	0.8

Schedule of Changes in Fair Value of Total Level 3 Financial Assets

The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the years ended December 31, 2022, 2021 and 2020 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of period		$	147	$	14,261	$	23,509
(Gain) loss recognized from the change in fair value of common stock warrants		(147)		1,386		17,087
Common stock warrants exercised during the period		—		(15,500)		(26,335)
Balance at end of period		$	—	$	147	$	14,261

Commitments and Contingencies (Detail) $ in Millions		1 Months Ended
Commitments and Contingencies (Detail) $ in Millions	Feb. 08, 2023 lawsuit	May 31, 2020 lawsuit	Dec. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Number of lawsuits \| lawsuit		3
Unsecured letter of credit outstanding			$ 4.9
Purchase obligation			351.4
Purchase obligation due within one year			$ 320.3
Subsequent Event
Loss Contingencies [Line Items]
Lawsuits dismissed \| lawsuit	2

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 444,384	$ 552,630
Maximum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents maturity term	3 months	3 months
U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 211,161	$ 221,724
Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	112,610	218,381
Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	18,114	58,836
Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	2,491	3,003
Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	595,126	600,916
Common stock warrants		147
Total liabilities		147
Fair Value, Measurements, Recurring \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	150,742	48,286
Fair Value, Measurements, Recurring \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	211,161	221,724
Fair Value, Measurements, Recurring \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	112,610	218,381
Fair Value, Measurements, Recurring \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	100,008	50,686
Fair Value, Measurements, Recurring \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	18,114	58,836
Fair Value, Measurements, Recurring \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	2,491	3,003
Fair Value, Measurements, Recurring \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	361,903	270,010
Common stock warrants		0
Total liabilities		0
Fair Value, Measurements, Recurring \| Level 1 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	150,742	48,286
Fair Value, Measurements, Recurring \| Level 1 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	211,161	221,724
Fair Value, Measurements, Recurring \| Level 1 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 1 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 1 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 1 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	233,223	330,906
Common stock warrants		0
Total liabilities		0
Fair Value, Measurements, Recurring \| Level 2 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 2 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 2 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	112,610	218,381
Fair Value, Measurements, Recurring \| Level 2 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	100,008	50,686
Fair Value, Measurements, Recurring \| Level 2 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	18,114	58,836
Fair Value, Measurements, Recurring \| Level 2 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	2,491	3,003
Fair Value, Measurements, Recurring \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	0
Common stock warrants		147
Total liabilities		147
Fair Value, Measurements, Recurring \| Level 3 \| Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 3 \| U.S. Treasury securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 3 \| Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Level 3 \| U.S. Government-sponsored enterprises
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 3 \| Corporate debt securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	0	0
Fair Value, Measurements, Recurring \| Level 3 \| Supranational bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt securities, available for sale	$ 0	$ 0

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Provision for Income Taxes

The income (loss) before provision for income taxes for the Company’s operations was as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
United States	$	(94,033)	$	15,211	$	(36,667)
Foreign	1,181		690		385
Income (loss) before provision for income taxes	$	(92,852)	$	15,901	$	(36,282)

Schedule of Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) were as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Current:
Federal	$	216	$	—	$	—
State	1,228		174		75
Foreign	298		161		151
Total current tax expense	1,742		335		226
Deferred:
Federal	—		—		(1,760)
State	—		—		(366)
Foreign	—		—		—
Total deferred income tax benefit	—		—		(2,126)
Income tax expense (benefit)	$	1,742	$	335	$	(1,900)

Schedule of Effective Income Tax Rate Reconciliation

The expense (benefit) for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands):


	Year Ended December 31,
	2022		2021		2020
Income tax expense (benefit) at federal statutory rate (1)	$	(19,499)	$	3,339	$	(7,619)
State income tax, net of federal benefit	(926)		(254)		(2,792)
Warrants revaluation	(31)		356		3,588
Research and development credits	(6,263)		(5,703)		(5,330)
Section 382 limitation	—		(97)		1,021
Stock-based compensation	2,282		(7,609)		(18,309)
Officers' compensation	2,931		4,024		2,612
Acquired IPR&D expenses	6,518		—		—
Other	962		124		479
Change in valuation allowance	15,768		6,155		24,450
Income tax expense (benefit)	$	1,742	$	335	$	(1,900)

(1)For the years ended December 31, 2022, 2021 and 2020, the federal statutory tax rate was 21%.

Schedule of Deferred Tax Assets and Liabilities


	December 31,
	2022		2021
Deferred tax assets:
Net operating loss (NOL) carryforwards	$	54,598	$	78,961
Research and development tax credits carryforwards	22,400		16,761
Capitalized research and development expenses	29,760		5,135
Accrued compensation	34,378		28,970
Lease liabilities	32,738		8,012
Other	20,927		20,608
Total deferred tax assets	194,801		158,447
Deferred tax liabilities:
Operating lease right-of-use assets	(26,505)		(6,637)
Fixed assets	(4,467)		(3,847)
Other	(1,103)		(1,540)
Total deferred tax liabilities	(32,075)		(12,024)
Less valuation allowance	(162,726)		(146,423)
Net deferred tax assets	$	—	$	—

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2022, 2021 and 2020 (in thousands):


	Year Ended December 31,
	2022		2021		2020
Gross unrecognized tax benefits at the beginning of the year	$	13,589	$	10,107	$	6,580
Increases related to current year positions	3,403		3,482		2,234
Increases (decreases) related to prior year positions	(6)		—		1,293
Gross unrecognized tax benefits at the end of the year	$	16,986	$	13,589	$	10,107

Employee-Benefits - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Retirement Benefits [Abstract]
Minimum age of employees for defined contribution plan	18 years
Contribution by company	$ 4.2

Business Segment and Geographic Information

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Business Segment and Geographic Information

Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable insulin cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as one segment and a single reporting unit because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

Disaggregation of Revenue

The Company primarily sells its products through national and regional distributors in the United States on a non-exclusive basis, and through distribution partners outside the United States. In the United States and Canada, the Company also uses a direct sales force. The Company disaggregates its revenue by geography and by major sales channel as management believes these categories best depict how the nature, amount and timing of revenues and cash flows are affected by economic factors.

Revenues by Geographic Region and Customer Sales Channel

During the years ended December 31, 2022, 2021 and 2020, no individual country outside the United States generated revenue that represented more than 10% of total revenue. The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped (in thousands):


	Year Ended December 31,
		2022		2021		2020
United States		$	588,765	$	524,907	$	415,680
Outside the United States		212,452		177,892		83,150
Total Sales		$	801,217	$	702,799	$	498,830

Sales to distributors accounted for 65%, 67%, and 70% of the Company’s total United States sales for the years ended December 31, 2022, 2021 and 2020, respectively. Sales to distributors accounted for 96%, 95%, and 94% of the Company’s total sales outside the United States for the years ended December 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	San Diego, California
Auditor Firm ID	42

Stockholders' Equity - Allocation of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 84,918	$ 60,752	$ 58,431
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	7,685	6,434	8,210
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	57,196	43,567	41,563
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 20,037	$ 10,751	$ 8,658

Business Segment and Geographic Information - Additional Information (Detail) - segment	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue, Major Customer [Line Items]
Number of operating segments	1
United States \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Revenue, Major Customer [Line Items]
Customers accounted for 10% or more	65.00%	67.00%	70.00%
Outside the United States \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk
Revenue, Major Customer [Line Items]
Customers accounted for 10% or more	96.00%	95.00%	94.00%

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Shares of Common Stock Reserved for Future Issuance

The following shares of the Company's common stock were reserved for future issuance at December 31, 2022 (in thousands):


Shares reserved for issuance upon conversion of Convertible Senior Notes			2,554
Shares underlying outstanding warrants			194
Shares underlying outstanding stock options			4,442
Shares underlying unvested restricted stock units			1,834
Shares authorized for issuance pursuant to awards granted under the ESPP			953
Shares authorized for future equity award grants			119
Total			10,096

Schedule of Stockholders' Equity Common Stock Warrants

Warrants outstanding to purchase shares of the Company's common stock as of December 31, 2022 were as follows:

Issue Date

Exercise Price Per Share

Warrants Outstanding

Expiration Date of Warrants Outstanding

March 2017

$23.50

193,788

March 2027

Schedule of Stock Option Activities for 2006 Plan and 2013 Plan

The following table summarizes stock option activities for the 2006 Plan and 2013 Plan:


	Total Options	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2019	7,174,927	$	38.40	8.45	$	181,408
Granted	1,130,040	$	83.55
Exercised	(2,339,467)	$	24.69		$	161,688
Canceled/forfeited/expired	(161,995)	$	27.00		$	4,516
Outstanding at December 31, 2020	5,803,505	$	52.08	7.90	$	268,649
Granted	355,008	$	86.68
Exercised	(1,128,791)	$	37.05		$	86,149
Canceled/forfeited/expired	(214,876)	$	76.29		$	6,963
Outstanding at December 31, 2021	4,814,846	$	57.08	7.07	$	452,081
Granted	83,008	$	65.28
Exercised	(280,275)	$	32.58		$	13,473
Canceled/forfeited/expired	(175,266)	$	77.93		$	2,143
Outstanding at December 31, 2022	4,442,313	$	57.95	6.12	$	30,236
Vested and expected to vest at December 31, 2022	4,423,803	$	57.87	6.12	$	30,236
Exercisable at December 31, 2022	3,701,918	$	54.08	5.82	$	30,234

Schedule of Restricted Stock Units

The following table summarizes RSU activities, which includes performance-based RSUs, for the 2013 Plan:


	Total RSUs	Weighted-Average Grant Date Fair Value		Aggregate Intrinsic Value (in thousands)
Unvested awards outstanding at December 31, 2019	—	$	—	$	—
Granted	134,694	$	82.82
Vested	(1,892)	$	82.34
Unvested awards outstanding at December 31, 2020	132,802	$	82.82	$	12,706
Granted	564,034	$	96.37
Vested	(53,957)	$	82.74
Canceled/forfeited	(32,148)	$	87.21
Unvested awards outstanding at December 31, 2021	610,731	$	95.08	$	91,927
Granted	1,542,859	$	67.09
Vested	(202,215)	$	91.99
Canceled/forfeited	(117,543)	$	84.20
Unvested awards outstanding at December 31, 2022	1,833,832	$	72.57	$	82,431
Awards expected to vest at December 31, 2022	1,797,999	$	72.62	$	80,820

Schedule of Compensation Cost Included in Consolidated Statement of Operations

The following table summarizes the allocation of stock-based compensation expense included in the consolidated statements of operations for all stock-based compensation arrangements (in thousands):


	Year Ended December 31,
		2022		2021		2020
Cost of sales		$	7,685	$	6,434	$	8,210
Selling, general and administrative		57,196		43,567		41,563
Research and development		20,037		10,751		8,658
Total stock-based compensation expense		$	84,918	$	60,752	$	58,431

Schedule of Assumptions Used in Black-Scholes Option-Pricing Model

The Company estimates the fair value of stock options using the Black-Scholes option-pricing model on the grant date. The assumptions used in the Black-Scholes option-pricing model were as follows:


		Stock Options
	Year Ended December 31,
		2022			2021			2020
Weighted average grant date fair value (per share)		$	42.16		$	56.89		$	54.20
Risk-free interest rate		2.7		%	1.0		%	0.6		%
Dividend yield		0.0		%	0.0		%	0.0		%
Expected volatility		72.0		%	75.1		%	74.6		%
Expected term (in years)		5.8			6.1			6.1

Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The assumptions used in the Black-Scholes option-pricing model for the ESPP were as follows:


					ESPP
	Year Ended December 31,
		2022			2021			2020
Weighted average grant date fair value (per share)		$	21.89		$	38.19		$	36.83
Risk-free interest rate		3.4		%	0.2		%	0.2		%
Dividend yield		0.0		%	0.0		%	0.0		%
Expected volatility		56.9		%	44.2		%	60.3		%
Expected term (in years)		1.3			1.3			1.3

Stockholders' Equity - Summary of Stock Option Activities for 2006 Plan and 2013 Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding at beginning of period (in shares)	4,814,846	5,803,505	7,174,927
Options, Granted (in shares)	83,008	355,008	1,130,040
Options, Exercised (in shares)	(280,275)	(1,128,791)	(2,339,467)
Options, Canceled/forfeited (in shares)	(175,266)	(214,876)	(161,995)
Options, Outstanding at end of period (in shares)	4,442,313	4,814,846	5,803,505	7,174,927
Options, Vested and expected to vest at December 31, 2022 (in shares)	4,423,803
Options, Exercisable at December 31, 2022 (in shares)	3,701,918
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price Per Share, Outstanding at beginning of period (in dollars per share)	$ 57.08	$ 52.08	$ 38.40
Weighted-Average Exercise Price Per Share, Granted (in dollars per share)	65.28	86.68	83.55
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)	32.58	37.05	24.69
Weighted-Average Exercise Price Per Share, Canceled/forfeited (in dollars per share)	77.93	76.29	27.00
Weighted-Average Exercise Price Per Share, Outstanding at end of period (in dollars per share)	57.95	$ 57.08	$ 52.08	$ 38.40
Weighted-Average Exercise Price Per Share, Vested and expected to vest at December 31, 2022 (in dollars per share)	57.87
Weighted-Average Exercise Price Per Share, Exercisable at December 31, 2022 (in dollars per share)	$ 54.08
Weighted-Average Remaining Contractual Life, Outstanding	6 years 1 month 13 days	7 years 25 days	7 years 10 months 24 days	8 years 5 months 12 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest	6 years 1 month 13 days
Weighted-Average Remaining Contractual Life, Exercisable	5 years 9 months 25 days
Aggregate intrinsic value outstanding balance	$ 30,236	$ 452,081	$ 268,649	$ 181,408
Aggregate Intrinsic Value, Exercised	13,473	86,149	161,688
Aggregate Intrinsic Value, Canceled/forfeited/expired	2,143	$ 6,963	$ 4,516
Aggregate Intrinsic Value, Vested and expected to vest	30,236
Aggregate Intrinsic Value, Exercisable	$ 30,234

Composition of Certain Financial Statement Items - Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Intangible assets, gross amount	$ 12,502	$ 12,502
Accumulated amortization	(7,875)	(5,866)
Intangible assets, net	$ 4,627	$ 6,636
Weighted average remaining amortization period (in months)	30 months	41 months

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Capillary Biomedical Acquisition On July 21, 2022, the Company acquired Capillary Biomedical, Inc. (Capillary Biomedical) an infusion set developer, for total cash consideration of $24.7 million, and the assumption of $4.7 million of long-term debt. The debt becomes due and payable upon the first sale or license of the commercialized product, and is included as a component of other long-term liabilities on the consolidated balance sheet at December 31, 2022. Capillary Biomedical’s extended-wear infusion set technology is currently in development and is not yet commercially available. The Company funded the purchase price using existing cash balances. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets were concentrated in a single asset. The Company recorded a $31.0 million charge representing the value of acquired in-process research and development assets with no alternative future use, and acquisition related expenses, on its consolidated statements of operations in acquired in-process research and development expenses. The Company’s results of operations for the year ended December 31, 2022 included the operating results of Capillary Biomedical since the date of acquisition, the amounts of which were not material.

Composition of Certain Financial Statement Items - Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 119,044	$ 114,974
Less: allowance for credit losses	(4,327)	(4,249)	$ (3,857)	$ (3,304)
Accounts receivable, net	$ 114,717	$ 110,725

Fourth Quarter Financial Data (Unaudited) - Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) - basic	$ (15,853)	$ 10,808	$ (94,594)	$ 15,566	$ (34,382)
Less: change in fair value of common stock warrants	0	32
Net income (loss) - diluted	$ (15,853)	$ 10,840	$ (94,594)	$ 15,566	$ (34,382)
Weighted average shares outstanding - basic (in shares)	64,384	63,650	64,146	63,000	60,990
Dilutive common share equivalents:
Common stock (in shares)			0	157	0
Weighted average shares used to compute diluted net income (loss) per share (in shares)	64,384	65,927	64,146	64,349	60,990
Options to purchase common stock
Dilutive common share equivalents:
Common stock (in shares)	0	1,877
Unvested restricted stock units
Dilutive common share equivalents:
Common stock (in shares)	0	227
Warrants to purchase common stock
Dilutive common share equivalents:
Common stock (in shares)	0	170
Awards to be granted under the ESPP
Dilutive common share equivalents:
Unvested and granted (in shares)	0	3

Composition of Certain Financial Statement Items (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable

Accounts receivable, net consisted of the following at December 31, 2022 and December 31, 2021 (in thousands):


	December 31,
	2022		2021

Accounts receivable	$	119,044	$	114,974
Less: allowance for credit losses	(4,327)		(4,249)
Accounts receivable, net	$	114,717	$	110,725

Schedule of Reconciliation of Change in Estimated Allowance for Doubtful Accounts

The following table provides a reconciliation of the changes in the allowance for estimated accounts receivable credit losses for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
		2022		2021		2020
Balance at beginning of the period		$	4,249	$	3,857	$	3,304
Provision for expected credit losses		4,782		2,333		3,016
Write-offs and adjustments, net of recoveries		(4,704)		(1,941)		(2,463)
Balance at end of the period		$	4,327	$	4,249	$	3,857

Schedule of Inventory

Inventories consisted of the following at December 31, 2022 and December 31, 2021 (in thousands):


	December 31,
	2022		2021

Raw materials	$	39,207	$	26,911
Work-in-process	18,571		16,612
Finished goods	53,339		25,028
Total inventories	$	111,117	$	68,551

Schedule of Property and Equipment

Property and equipment, net consisted of the following at (in thousands):


	December 31,
	2022		2021
Leasehold improvements	$	35,828	$	25,245
Office furniture and equipment	13,772		9,943
Computer equipment and software	12,330		11,544
Manufacturing and scientific equipment	62,797		52,823
Total cost	124,727		99,555
Less: accumulated depreciation and amortization	(56,175)		(49,169)
Total property and equipment, net	$	68,552	$	50,386

Schedule of Capitalized Patents


	December 31,
	2022		2021
Intangible assets, gross amount	$	12,502	$	12,502
Accumulated amortization	(7,875)		(5,866)
Intangible assets, net	$	4,627	$	6,636
Weighted average remaining amortization period (in months)	30		41

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	64,513,000	63,833,000
Common stock, shares outstanding (in shares)	64,513,000	63,833,000

Stockholders' Equity - Assumptions Used in Black-Scholes Option-Pricing Model (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value - options (in dollars per share)	$ 42.16	$ 56.89	$ 54.20
Risk-free interest rate	2.70%	1.00%	0.60%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	72.00%	75.10%	74.60%
Expected term (in years)	5 years 9 months 18 days	6 years 1 month 6 days	6 years 1 month 6 days
Awards granted under the ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value (in dollars per share)	$ 21.89	$ 38.19	$ 36.83
Risk-free interest rate	3.40%	0.20%	0.20%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	56.90%	44.20%	60.30%
Expected term (in years)	1 year 3 months 18 days	1 year 3 months 18 days	1 year 3 months 18 days

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2021 shares
Common Stock Warrant Expiring October 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Outstanding warrants (in shares)	1,000

Short-Term Investments - Estimated Fair Value of Short-Term Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	$ 447,241	$ 553,254
Gross Unrealized Gain	30	15
Gross Unrealized Loss	(2,887)	(639)
Estimated Fair Value	444,384	552,630
U.S. Treasury securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	213,105	222,206
Gross Unrealized Gain	3	0
Gross Unrealized Loss	(1,947)	(482)
Estimated Fair Value	211,161	221,724
Commercial paper
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	112,812	218,391
Gross Unrealized Gain	6	14
Gross Unrealized Loss	(208)	(24)
Estimated Fair Value	112,610	218,381
U.S. Government-sponsored enterprises
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	100,602	50,773
Gross Unrealized Gain	21	1
Gross Unrealized Loss	(615)	(88)
Estimated Fair Value	100,008	50,686
Corporate debt securities
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	18,218	58,881
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(104)	(45)
Estimated Fair Value	18,114	58,836
Supranational bonds
Cash Cash Equivalents And Short Term Investments [Line Items]
Amortized Cost	2,504	3,003
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(13)	0
Estimated Fair Value	$ 2,491	$ 3,003

Fair Value Measurements - Changes in Fair Value of Total Level 3 Financial Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 147	$ 14,261	$ 23,509
(Gain) loss recognized from the change in fair value of common stock warrants	(147)	1,386	17,087
Common stock warrants exercised during the period	0	(15,500)	(26,335)
Balance at end of period	$ 0	$ 147	$ 14,261
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Change in fair value of common stock warrants	Change in fair value of common stock warrants